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Glucose is the major substrate for energy production in the central nervous system. 
Prolonged reduction of cerebral glucose concentration inevitably leads to neuronal 
damages and eventually affects brain functioning. Epilepsy is one of the major symptoms 
in diseases relating to prolonged glucose deficiency such as glucose transporter type I 
(Gliitl) deficiency syndrome and Alzheimer's disease. The present study focused on 
investigating the relationship between prolonged glucose deficiency and the etiology of 
the pro-epileptic symptoms such as the accumulation of extracellular glutamate. Provided 
that astrocytes are the major site for glutamate uptake in the brain, an in vitro model of 
primary cultured rat astrocytes was used in the experiments. Upon reducing the glucose 
concentration from 3 mM to 1 mM, we observed a significant decrease in glutamate 
transporter type 1 (GLT-1) expression (p<0.05) through the extracellular signal regulated 
kinase (ERK)-dependent pathway. However, no significant change was found in 
> 
glutamate uptake. Further investigations showed that Glutl gene expression and glucose 
uptake were stimulated, corresponding to the induction of interleukin-6 (IL-6) release by 
ii 
astrocytes. Taken together, under prolonged glucose deficiency, astrocytes may increase 
the energy availability to compensate for the reduced glutamate transporter expression, 








模型。當葡萄糖的濃度由 3 m M降至 1 mM，我們觀察到谷氨酸轉運蛋白（GLT-1) 
透過細胞外信號調節激酶（ E R K )相關的訊息傳遞通路而導致表達顯著下降 
(p<0.05)�但谷氨酸的攝取卻沒有顯著的改變。進一步的研究顯示從星狀細胞中釋放 
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CHARPTER 1 INTRODUCTION 
Glucose is the major substrate for energy production in the central nervous 
system (CNS). A deficiency of glucose in the CNS may cause serious neuronal 
damages due to oxidative stress, mitochondrial damages (Delgado-Esteban, 2002), 
impairment of synaptic transmission (Ikemoto et. ai, 2003) and inability to regulate 
calcium homeostasis (Kahlert and Reiser, 2004). A number of diseases had been 
found to correlate with the decreased brain glucose level, such as glucose transporter 
type 1 deficiency syndrome (GlutlDS; De Vivo et. al., 1991), Alzheimer's disease 
(AD; Kalaria and Harik, 1989) and diabetes mellitus (DM; McCall, 2004). Epilepsy is 
one of the clinically observed symptoms in these patients (Flykanaka-Gantenbein, 
2004; Amatniek et. al., 2006; De Vivo et. al., 2002). Thus, the current project focused 
on investigating the relationship between prolonged glucose deficiency and the cause 
of epileptic symptoms using an in vitro model. 
1.1 Glucose Transport through the Blood Brain Barrier 
i 
The blood brain barrier (BBB) is composed of brain capillaries with endothelial 
cells tightly packed together which is around 50 to 100 times tighter than peripheral 
1 
microvessels (Abbott, 2002). They form tight junctions (zonula occludens) which 
restrict the entry of a variety of substances, except for those that can enter the brain by 
simple diffusion (oxygen, carbon dioxide and water) and lipid-mediated penetration 
(ethanol, caffeine and amphetamine; Cornford et. al., 1982). Hydrophilic substances 
such as glucose can only pass through the BBB via the mediation of glucose 
transporters. 
Facilitative glucose transporters (Gluts) exist in thirteen different isofomis 
(Glutl-Glutl2 and the H+/inyoinositiol co-transporter; Joost and Thorens, 2001; 
McVie-Wylie et. al., 2001; Phay et. al, 2000). Among these, Glutl is the major 
isoform ubiquitously expressed at the endothelial cells of the BBB (Comford and 
Hyman, 2005). Glutl protein, as a result of differential glycosylation, can be 
subdivided into two i so forms with molecular weights of 45 kDa and 55 kDa. The 45 
kDa protein is found on astrocytes, while the 55 kDa protein on the luminal and 
abluminal membranes of the endothelial cells of the BBB (Duelli et. al., 2001; Lei no 
et, al., 1997; Maher et. al., 1994), suggesting the importance of astrocytes in 
regulating glucose level in the CNS. 
Glutl protein has a relatively low Km value of around 3 mM (Wieczorke et. al, 
2003), suggesting that the brain is preferentially supplied with glucose even when the 
blood glucose level falls significantly below normal which is about 5 mM. At the 
2 
BBB, glucose is transported by Gliitl down the concentration gradient from the blood 
into the brain endothelial cells where the concentration drops to around 3 niM. 
Glucose is further transported into the cerebral spinal fluid (CSF) with glucose 
concentration of 2.7 mM (Figure 1.1). 
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Figure 1.1 Schematic diagram of the transport of glucose across the blood brain 
barrier. Glucose is transported down the concentration gradient from the blood to 
astrocytes via Glutl proteins. (Modified from Duelli and Kuschinsky, 2001) 
I 
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1.2 Roles of Astrocytes in the Brain 
Astrocytes are spindle-shaped cells formed in the CNS. They were initially 
called "Nervenkitt", which means "the glue that holds the neurons together” 
(Dennietzel and Spray, 1998). In addition to neurons, supporting cells in the brain can 
be classified into two major groups, namely the macroglia and microglia. Macroglia 
can be further subdivided into oligodendrocytes and astrocytes (Kurosinski and Gotz, 
2002). On the other hand, microglia are few and they play a role in phagocytosis and 
inflammatory responses. Glial cells differ from neurons in that they possess no 
synaptic structures and retain the ability to divide, particularly in response to injury. 
Astrocytes, the most abundant cell types, are distributed both in the gray and 
white matters, and the ratio of glia to neurons is about 10:1 in the CNS (Kurosinski 
and Gotz, 2002). They are characterized by their large starry-shaped cell bodies and 
many radiating processes (Nedergaard et. ai, 2003). Two types of astrocytes namely 
fibrous and protoplasmic astrocytes were classified. Protoplasmic astrocytes are 
characterized-by thick, branched processes with spiny projections and are localized > 
primarily within the gray matter. The fibrous astrocytes, in contrast, consisting of 
relatively long and thin processes with few branches, are the predominant type in the 
white matter. Astrocytes can be immunostained with glial fibrillary acidic protein 
4 
(GFAP), a cytoskeletal marker protein (Figure 1.2) (Eng et al.’ 2000), and SIOOB, a 
cytosolic calcium-binding protein (Tagliaferro et. al., 2002). 
Figure 1.2 Astrocytes immunostained with glial fibrillary acidic protein. Fibrous 
astrocytes immunostained with GFAP giving a green fluorescent signal. Thin and long 
processes are the characteristics of this type of astrocytes (Adopted from 
http://www.bergleslab.com). 
Astrocytes were initially believed to be simply a physical supporting element for 
neurons in the CNS. The cytoplasmic projections of astrocytes provide a non-rigid 
supportive framework and insulating matrix for neurons (Kurosinski and Gotz, 2002). 
However, recent advances in neuroscience revealed the dynamic roles of astrocytes in 
brain development. 
It was found that astrocytes are important for the strict regulation of the 
5 
extracellular ionic homeostasis which is critical for the normal functioning of neurons. 
For instance, physiological concentration of extracellular KT ion is maintained by 
either passive diffusion or active uptake via the Na+/K十 ATPase into astrocytes. 
Furthermore, in order to maintain a constant pH for various vital processes, the 
concentration of H+ ion is regulated by Na+/H+ and ClVHCOs" exchangers that are also 
found in astrocytes (Simard and Nedergaard, 2004). 
Under physiological conditions, various neurotrophic factors are secreted from 
astrocytes to regulate neuronal survival, development, functioning and plasticity 
(Korsching, 1993; Hide et. ciL, 1993; Sofroniew et. al., 2001). Examples include 
different kinds of neurotrophins (e.g. neurotrophic growth factor, brain-derived 
neurotrophic factor and neiirolrophin-3), cytokines (e.g. interleukin-6) and calcium 
binding proteins (e.g. SIOOB). Cholesterol, which contributes the promotion of 
synaptic formation (Mauch et. al., 2001), is believed to be transported from astrocytes 
to neurons by apolipoprotein E (apoE; Goritz et. al., 2002). 
Under pathological conditions or in brain injuries, astrocytes also provide 
supportive functions to neurons. It has been found that astrocytes respond to injured > 
events by inducing astrogliosis to minimize further damages (McGraw et al, 2001). 
Such process is characterized by cellular hypertrophy, proliferation and 
overexpression of GFAP (Eng et ciL, 2000). Astrogliosis is usually followed by scar 
6 
formation which is important for the recovery of the tensile strength of the tissue and 
to protect other intact parts from secondary damages (Ridet et. al., 1997). However, 
studies also suggested undesirable effects of glial scar formation in hindering the 
regeneration of neurons. For example, the scars formed by interwoven astrocytic 
processes block axonal regeneration. Besides, proteoglycans, like chondroitin 
sulphate proteoglycan, secreted from reactive astrocytes were found to inhibit the 
growth of neurons (Fawcett and Asher, 1999). These suggested that astrocytes play 
more than a supporting role in the CNS. 
Reports also found that receptors for different neurotransmitters, such as 
dopamine, gamma aminobutyric acid, glycine, serotonin and p-adrenergic receptors, 
are present on astrocytes (Temburni and Jacob, 2001), indicating that astrocytes are 
able to receive signals from neurons and may probably trigger intracellular cascades 
within the cell (Verkhratsky and Steinhauser, 2000). Moreover, the presence of 
transporters on astrocytes allows active removal of excessive neurotransmitters from 
the synaptic cleft. One example is the Na+-dependent glutamate transporters which 
facilitate the uptake of extracellular glutamate, thus reducing glutamate toxicity and 
» 
neuronal cell death (Anderson and Swanson, 2000). 
Moreover, astrocytes have been suggested to play a role in BBB functioning. 
BBB fonned with capillary endothelial cells is almost completely enwrapped by the 
7 
end-foot processes of astrocytes (Hamm et. al., 2004). Studies on glial-BBB 
relationship showed that astrocytes were able to regulate the tight-junction formation 
between endothelial cells and to increase BBB permeability during focal cerebral 
ischemia (Ballabh et cil., 2004). 
In addition, glial cells also play a role in brain development. Radial glia, arisen 
from the embryonic stage during brain development, were found to aid the migration 
of neurons during neurogenesis. In this process, radial glia, with the adhesion 
molecules present on the surface, are believed to be responsible for the guidance of 
neurons to the appropriate locations in the CNS. After neurogenesis is completed, 
radial glia would transform into protoplasmic astrocytes (Gotz and Huttner, 2005). 
1.3 Glucose Metabolism in Astrocytes 
Glucose taken into astrocytes via Glutl undergoes glycolysis to produce 
pyruvate and adenosine triphosphate (ATP) via the tricarboxylic acid (TCA) cycle 
(Figure 1.3). I-n astrocytes, there also present lactate dehydrogenase (LDH) 5 in which > 
the glycolytic product pyruvate can be reversibly converted into lactate. The lactate 
formed can be transported to the surrounding neuronal cells via monocarboxylate 
transporter 1 and 2. LDH-1 then converts lactate back to pyruvate which enters the 
8 
TCA cycle to produce energy. It is believed that neurons are the major energy 
consumer in the brain (Attwell and Laughlin, 2001), but unlike astrocytes, they do not 
possess the glycogen storage system. Thus, it is hypothesized that lactate supplied by 
astrocytes is the main energy substrate for neurons (Chih et al., 2001; Dringen et al, 
1993) (Figure 1.3). This proposal suggests that glucose transporters in astrocytes play 





Figure 1.3 Energy production in astrocytes via glucose metabolism. Glucose taken 
into by astrocytes via Glutl undergoes glycolysis to produce pyruvate. ATP, which is a 
universal energy source, is generated in the process. Further energy is produced when 
pyruvate enters the TCA cycle. Lactate would also be formed from pyruvate and 
would be supplied to neurons for further energy production. (Modified from Pellerin 
and Magistretti, 1994) 
9 
1.4 Diseases Associated with Reduced Glucose Transport 
The Km value of Glutl transporters present on the BBB is about 3 mM 
(Wieczorke et. al., 2003), suggesting the brain would be preferentially supplied with 
glucose even under starvation. Further suggests that if the transporters were 
dysfunctional, the brain would inevitably suffer from glucose deficiency and the 
subsequent damages. In recent decades, a number of diseases had been found to be 
associated with decreased glucose transport at the BBB and they are briefly described 
below. 
Diabetes mellitus can be divided into type 1 and 2. Type 1 DM is also called 
insulin-dependent DM, and patients lack the ability to produce insulin by the pancreas 
possibly because of an autoimmune attack. Type 2 DM is also called 
non-insulin-dependent DM. Patients suffering from this condition can still produce 
insulin, but the sensitivity of the cells (particularly fat and muscle cells) to insulin has 
been reduced. Besides, the insulin produced may also be malfunctional or suboptimal. 
For type 1 DM, insulin replacement therapy is an effective way to supplement the 
inadequate production of insulin (Korc, 2004). However, in some severe DM cases, 
the patients may suffer from the inability to recognize low blood glucose in the body, 
or hypoglycemic unawareness (Hirst, 2004). Reports suggested that prolonged 
10 
hypoglycemia may cause cognitive disruption, convulsions and unconsciousness 
(Mohseni, 2001). In addition, the Glutl protein expression and the glucose transport 
at the BBB were reduced (McCall et. al., 1982; Duelli et. al., 2000). 
In addition to DM, Glutl DS which was firstly announced in 1991 is 
characterized with a reduction in cerebral glucose level. GlutlDS is an autosomal 
dominant disease. In 1998, the first GlutlDS patient possessing a large-scale deletion 
at one allele of the GLUTl gene was identified (Seidner et. al.’ 1998). Different types 
of mutations have been subsequently found in GlutlDS patients. They include 
missense, nonsense, insertion, deletion, and slice-site mutations (Wang et. al., 2005) 
(Figure 1.4). 
The clinical characteristics of GlutlDS are infantile-onset epileptic 
encephalopathy, deceleration of head growth, acquired microcephaly, delays in mental 
and motor development, spasticity, ataxia and dysarthria (De Vivo et. al., 2002; 
Klepper et. al., 1999). In these patients, though they have normal blood glucose level, 
the CSF glucose concentration is reduced to lower than 40 mg/dL. Besides, cerebral 
fluoro-deoxy-glucose positron emission tomography revealed a global decrease in > 
glucose uptake with relative preservation of basal ganglia metabolism (Pascual et. al,, 
2002). Experimental findings also confinned such phenomenon. For instance, in 
erythrocytes, where the Glutl proteins expressed are immunologically and chemically 
11 
similar to those expressed in cerebral microvessels (Kalaria et. al., 1988)，there was a 
reduction of approximately 50% in the 3-0-niethyl-D-glucose (3-OMG) uptake in 
GlutlDS patients relative to normal individuals (Klepper et. al., 1999). All these 
suggested a defect in Glutl in these patients. 
Seizures usually appear within the first four months of age in affected infants. 
Apneic episodes and abnormal episodic eye movements simulating opsoclonus may 
precede the onset of seizures by several months. Five seizure types occur: generalized 
tonic or clonic, myoclonic, atypical absence, atonic, and unclassified seizures. The 
frequency of seizures varies among affected individuals (von Moers et. cd., 2002; 
Leary et. al., 2003). Besides, findings also suggested that fasting would trigger the 
epileptic symptoms in some of these patients (Brockmann et. al., 2001). However, the 
actual cause of epileptic symptoms in GlutlDS patients is not known. 
> 
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Figure 1.4 Summary of the mutations identified in the Glutl gene causing 
GlutlDS. Filled boxes represent the 10 exons and the lines represent the introns. 15 
different missense mutations are listed on the left hand side; the other mutations 
including nonsense, insertion, deletion, and slice-site mutations are listed on the right 
side. The superscript numbers represent the number of patients sharing the same 
mutation. (Wang et. al., 2005). 
1.5 Extracellular Accumulation of Glutamate as a Cause for Epilepsy 
Accumulation of glutamate, an excitatory neurotransmitter, at the synapse have 
been known to cause seizure (Meldrum et. al., 1999; Watanabe et. al., 1999). In 
glutaminergic neurons, glutamate is accumulated at high concentrations in synaptic > 
vesicles. Upon stimulation, glutamate will be released into the synaptic cleft through 
calcium-dependent exocytosis (Gundersen et. al, 1998). Glutamate will then mediate 
excitation by activating the ionotropic receptors, both the a-amino-3-hydroxy-
13 
5-methyl-4-isoxazole propionate (AMPA)-type and N-methyl-D-aspartate 
(NMDA)-type, present on the postsynaptic neurons (Groc et. al., 2006). Due to the 
high neurotoxicity of excessive glutamate (Choi, 1988), it needs to be quickly 
removed from the synapse. It has been reported that the majority of glutamate would 
be taken up by astrocytes via glutamate transporters (Anderson and Swanson, 2000). 
Upon the uptake of glutamate into astrocytes, it will enter the 
glutamate-glutamine cycle (Boulland and Levy, 2005). Firstly, an amino group is 
added to the glutamate, with the help of glutamine synthetase, forming glutamine, a 
non-toxic amino acid. Glutamine formed will be released into the extracellular space 
and then taken up by surrounding neurons. Phosphate-activated glutaminase present 
in the neurons is responsible for the hydrolysis of glutamine back to glutamate (Hertz 
et. al.’ 1999) (Figure 1.5). In this process, astrocytes help in removing toxic glutamate 
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Figure 1.5 Glutamate uptake and glutamate-glutamine cycle in astrocytes and 
neurons. Glutamate released into the synapse will bind to the receptor on the 
postsynaptic membrane. Excessive glutamate will be taken up by astrocytes via 
glutamate transporters. Glutamate will then be converted into glutamine by glutamine 
synthetase. Glutamine released will enter the neurons for the production of glutamate 
by the action of glutaminase. (Modified from Anderson and Swanson, 2000) 
To date, two families of glutamate transporters had been identified: 
Na^-independent vesicular transporters and Na^-dependent transporters (Anderson 
and Swanson, 2000). Of these, Na十-dependent transporters play a more important role 
in regulating, the resting glutamate concentrations of about 0.6 mM in synapses 
(Bouvier et. al., 1992) by coupling the transport of potassium and sodium ions 
(Anderson and Swanson, 2000), so they are also known as the sodium and potassium 
coupled glutamate transporters, or in human, excitatory amino acid transporters 
15 
(EAATs) (Danbolt, 2001). Five different Na+-dependent glutamate transporters had 
been cloned: GLAST(EAATl), GLT-1 (EAAT2), EAAC1(EAAT3), EAAT4 and 
EAATS (Shigeri et. al., 2004). These transporters differ from each other by their 
regional and cellular localizations in the nervous system (Table 1.1). 
Glutamate Regional/Cellular Localization References 
Transporter 
GLAST (EAATl) Astrocytes, oligodendrocytes 
GLT-1 (EAAT2) Astrocytes, oligodendrocytes, neurons Utsumi et. al, 2001 
EAACl (EAAT3) Purkinje cells, neurons 
EAAT4 Cerebellar Purkinje cells Faimian et, al., 1995 
EAATS Retina Arriza e/. ai, 1997 
Table 1.1 Regional and cellular localizations of different types of glutamate 
transporters in the CNS. 
GLAST and GLT-1, the main transporters expressed by astrocytes, share about 
65% sequence homology and they possess similar hydropathy plots (Gegelashvili and 
Schousboe, 1997). It is believed that they are responsible for the clearance of 
glutamate from the synapse so as to prevent glutamate excitotoxicity. Whether 
GLAST or GLT-1 is more important on glutmate uptake is still controversial. It has 
been suggested that GLT-1 exhibits the highest level of expression and is thus 
responsible for most glutamate transport (Danbolt, 2001). In contrast, different 
GLAST-knockout studies revealed that GLAST is an important factor in keeping the 
physiological glutamate level (Kanai and Hediger, 2004). 
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1.6 Regulations of Astrocyte-mediated Glutamate Uptake 
Since an elevated glutamate level at the synapse is neurotoxic, prompt removal 
of excessive glutamate is essential. Astrocytes are the primary site for glutamate 
uptake at the synapse, and many reports had suggested the tight regulation of 
glutamate uptake by different signalling mechanisms in astrocytes. 
Mitogen-activated protein kinases (MAPKs) are one type of molecules which 
play an important role in regulating glutamate uptake in astrocytes. These kinases 
belong to a family of proteins, which contain the conserved proline-directed 
serine/threonine, and they were involved in intracellular signaling. Mammalian 
MAPKs were classified into four groups based on their structures and functions. They 
are the extracellular signal-regulated kinase (ERK; Robinson and Cobb, 1997), c-Jun 
N-tenninal kinase (JNK) or stress-activated protein kinase (SAPK; Kyriakis et. al, 
1994; Derijard et. al., 1994)，p38 MAPK (Han et. al., 1994; Rouse et. al., 1994; 
Freshney et. al., 1994) and ERK 5 or big MAPK (BMK; Zhou et. al., 1995; Lee et. “/., 
1995). . 
Reports suggested that various extracellular stimuli could elicit the activation of 
MAPK cascades, for example some growth factors, cytokines, and stresses (Pearson 
et. ciL, 2001). The activation begins by the phosphorylation at either the serine or 
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threonine residue of MAP/ERK kinase (MEK) by the MAP/ERK kinase kinase 
(MEKK). Then, the MAPKs would be activated by dual phosphorylation at the 
conserved threonine and tyrosine (TXY) motif by the activated MAP/ERK kinases 
(Pearson et, ciL, 2001; Zheng and Guan, 1994). Subsequently, biological responses 
such as cell growth, cell differentiation and apoptosis would be triggered (Figure 1.6). 
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Figure 1.6 An overview of the MAPK signalling pathways. (Modified from 
http://www.cellsignal.com/reference/pathway/MAPK_Cascade.asp) 
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Among the MAPKs, ERKl and ERK2 were the first members whose cDNAs 
were cloned (Boulton et. ai, 1990). ERKl (p44 MAPK) and ERK2 (p42 MAPK) 
have molecular weights of 44 kDa and 42 kDa, respectively, and they share about 
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85% homology (Pearson et. al., 2001). Recent researches revealed the neuroprotective 
role of ERK 1/2 in the CNS (Hetman and Gozdz, 2004). For instance, it was found that 
NMDA-induced neuronal death could be prevented by transforming growth factor a 
through the activation of astrocytic ERKl/2 (Gabriel et. al., 2003). On the other hand, 
ERK 1/2 activation in the CNS would hinder the astrocyte-mediated glutamate uptake. 
Abe and Misawa (2003) suggested that upon the activation of ERKl/2, the amyloid 
(3-induced upregulation of glutamate uptake in astrocytes was suppressed, and the 
effect could be reversed by the addition of ERKl/2 specific inhibitors. 
Cytokines, in addition to their inflammatory roles, are found related to the 
astrocyte-mediated glutamate transport mechanism. Cytokines are glycoproteins with 
low molecular weights. They act as intercellular messengers which mediate 
intercellular communication. Macrophages, monocytes, lymphocytes, endothelial 
cells, fibroblasts and platelets, upon activation, are able to produce cytokines to 
regulate cell functions during development and during defensive responses to 
infection, inflammatory, autoimmune, traumatic and ischemic injuries (Pantoni et. al, 
1998; Wang and Shuaib, 2002). Cytokines are secretory proteins, and the expression > 
and secretion were found to be regulated by different signaling pathways such as the 
ERKl/2 pathway (Ho et. al., 2005; Lee et. al., 2000). 
Tumor necrosis factor alpha (TNFa) is produced by a number of cell types such 
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as activated macrophages, monocytes and astrocytes upon stimulation (Benveniste, 
1993). As its name implies, TNFa was first found to be an anti-tumor agent, which 
causes necrosis in cancer cells in vivo. Besides, it can stimulate a number of cell types 
including macrophages for defense against intracellular pathogens (Wang and Shuaib, 
2002). In human, TNFa is synthesized at first as a 26 kDa membrane-bound precursor. 
After proteolytic cleavage by the metalloprotease, TNFa converting enzyme (Black et 
al, 1997), followed by trimerization, a soluble tightly-packed homotrimer with a size 
of 52 kDa is formed. By binding to its high affinity receptor, which consists of type I 
(p55) and type II (p75), TNFa exerts a variety of functions (Barger, 1998). 
Different studies have examined the relationship between an elevated level of 
TNFa and the elevated extracellular glutamate concentration. In the study, TNFa was 
found to activate nuclear factor kappa B ( N F K B ) , which is a transcription factor, by 
initiating I kappa B degradation. The activated N F K B was then translocated into the 
nucleus and was bound to the DNA. Such action repressed the EAAT2 expression, 
and thus reducing the glutamate uptake from the extracellular space (Sitcheran et. al., 
2005). Another finding also revealed the combined effect of TNFa and glutamate in 
provoking and amplifying neurotoxic effect (Hermann et. al., 2001). 
Up to dale, three kinds of interleukin (IL)-l namely IL- l a , IL-lp and IL-1 
receptor antagonist have been identified. I L - l a and IL-lp, sharing 60-70% homology, 
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were extensively studied. They are proteins which serve various functions inside the 
body, including the induction of fever, synthesis of prostaglandin and activation of 
T-lymphocyte (Dinarello, 1996). IL-1 mediates their functions through the binding 
onto the receptor IL-lRl and the activation of different signaling pathways such as 
p38 M A P K , cAMP-response element binding protein ( C R E B ) and N F K B (Srinivasan 
et. al, 2004). 
In addition, IL-1 a and IL-1 (3 were found to correlate with epilepsy. Upon the 
induction of seizure, IL-1 gene expression was found upregulated at different regions 
of the brain like the hippocampus, cortex and hypothalamus (Minami et. al., 1991). 
Another study also showed that microglia and astrocytes might be responsible for the 
increase of IL-1 p at and around lesion areas (Pearson et. al., 1999). For IL-1 a , reports 
suggested the relationship to seizure in animal models and in human. For instance, in 
an audiogenic seizure-susceptible mouse model, IL-1 a mRNA was upregulated in the 
hypothalamus (Gahring et. al., 1997). Besides, the increase of this protein, together 
with the increased level of p-amyloid precursor protein, was found to contribute to the 
excitotoxic neuronal death in human epileptic brains (Sheng et. al, 1994). > 
IL-6 is a neuropoietic cytokines with a molecular weight of around 24 kDa. It 
was found to express in different cell types in the CNS including neurons, microglia 
and astrocytes (Dihne et. al., 2001; Block et. al., 2000; Van Wagoner and Benveniste, 
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1999). IL-6 mediates various physiological functions, for example cell growth and 
differentiation and the induction of immune responses (Gruol and Nelson, 1997), 
through the binding to the IL-6 receptor present on the target cells. In addition, the 
gene expression of IL-6 had been found to elevate upon the induction of epilepsy in 
both animal models and in human brains (Minami et. al., 1991; Peltola et. al., 1998). 
1.7 Aim and Hypothesis of the Project 
For patients suffering from prolonged glucose deficiency in the brain caused by 
impaired Glutl function, epilepsy may result. The aim of this project is to investigate 
astrocytic responses under glucose deficient conditions in vitro. Given that Glutl is 
highly expressed in astrocytes and they are the primary sites for glucose metabolism 
and glutamate uptake from the synapse, we hypothesized that prolonged glucose 
deficiency would impair glutamate uptake in astrocytes and thus create a pro-epileptic 
condition (Figure 1.7). To test this hypothesis, the expressions of astrocytic glutamate 
transporters and glutamate uptake under prolonged glucose deficiency treatment will > 
be examined. 
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Figure 1.7 A hypothesis of the cause of glucose deficiency-induced epilepsy. Based 
on previous findings, we hypothesize that prolonged glucose deficiency causes the 
downregulalion of astrocytic glutamate transport. The subsequent decrease in 
glutamate uptake from the extracellular spaces leads to the accumulation of glutamate, 
creating a pro-epileptic condition. 
> 
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CHAPTER 2 MATERIALS & METHODS 
2.1 Materials 
2.1.1 Primary Rat Astrocytes 
The primary cultured rat astrocytes were isolated from two-day-old 
Sprague-Dawley (SD) rats obtained from the Laboratory Animal Services Centre at 
The Chinese University of Hong Kong (H.K.S.A.R., China). 
2.1.2 Cell Culture Materials 
High glucose Dulbecco's Modified Eagle medium (D-MEM) was prepared by 
dissolving one pack of high glucose D-MEM powder (Gibco, Carlsbad, C.A., U.S.A.) 
in one litre of NANOpure water with the addition of 44.04 mM of sodium bicarbonate 
(NaHC03; Sigma, St. Louis, M.O., U.S.A.) and 20 mM of > 
4-(2-hydroxyethyl)piperazine-l-ethanesulfonic acid (HEPES; Sigma, St. Louis, M.O., 
U.S.A.). Glucose-free D-MEM was prepared by dissolving 8.3 g of D-MEM base 
powder (IJSBiological, Swampscott, M.A., U.S.A.), together with 0.201 mM of 
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L-cystine, 4 inM of L-glutamine, 0.0499 niM of phenol red, 44.05 mM of NaHCO.n 
and 20 mM of HEPES (Sigma, St. Louis, M.O., U.S.A.) in one litre of NANOpure 
water. For both media, the pH was adjusted to 7.3 then filtered through an 0.22 jam 
filter (Millipore, Billerica, Billerica, M.A., U.S.A.) under sterilized conditions. The 
medium was stored at 4"C until use. 
The heat-inactivated fetal bovine serum (FBS) was purchased from Gibco 
(Carlsbad, C.A., U.S.A.). Aliquots of 40 ml were kept at - 2 0 � C until use. 
Penicillin-streptomycin (PS) antibiotic mixture containing 10,000 units/ml penicillin 
and 10 mg/ml streptomycin purchased from Gibco (Carlsbad, C.A., U.S.A.) was 
stored at -20"C as 10 ml aliquots until use. Both 0.05% and 0.25% 
trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA) solutions were purchased 
from Gibco (Carlsbad, C.A., U.S.A.). The 0.05% trypsin-EDTA solution contains 
0.05% trypsin and 0.53 mM of EDTA-4Na in Hanks' balanced salt solution; while the 
0.25% trypsin-EDTA solution contains 0.25% trypsin and 1 mM EDTA-4Na in 
Hanks' balanced salt solution. Aliquots were prepared for all of the above reagents 
and were stored at -20°C until use. > 
Phosphate-buffered saline (PBS) was prepared by dissolving one pack of 
Dulbecco's PBS powder (Gibco, Carlsbad, C.A., U.S.A.) in one litre of NANOpure 
water, autoclaved and stored al 4 � C until use. 2 M of glucose solution was prepared by 
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dissolving 9.9 g of glucose powder (Sigma, St. Louis, M.O., U.S.A.) in 50 ml of 
NANOpure water, and stored at -20°C as 10 ml aliquots until use. 
2.1.3 Chemicals 
Recombinant mouse IL-6 (2 jLig/ml) was purchased from Roche Diagnostics 
(Mannheim, G.E.R.). It was stored in aliquots at -20°C until use. This cytokine was 
found to be active in primary cultured rat astrocytes (Chang et. al, 2001). MEK 
specific inhibitor, U0126 (1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)-
butadiene), was purchased from CalBiochem (San Diego, C.A., U.S.A.). It was 
dissolved in absolute dimethyl sulfoxide (DMSO) and the stock solution was stored 
at -20°C until use. Culture medium was used to dilute the drugs into various 
concentrations for different experiments. 
2.1.4 Reagents for the Determination of Gene Expressions 
> 
TRIzol® reagent (Invitrogen, Carlsbad, C.A., U.S.A.) was stored at 4 T , while 
isopropanol, chloroform and 70% ethanol were stored at room temperature until use. 
The last three agents were analytical grade and were obtained from Sigma (St. Louis, 
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M.O., U.S.A.). 
Deoxynucleotide triphosphate mix (dNTP; containing 10 mM for each dNTP), 
random primer p(dN)6 (2 |ag/ml) and RNase inhibitor (50 U/fil) purchased from 
Roche Diagnostics (Mannheim, GE.R.); SuperScript^^-II Reverse Transcriptase, 5x 
first-strand buffer and 100 mM of dithiothreitol (DTT) purchased from Invitrogen 
(Carlsbad, C.A., U.S.A.)； and nuclease-free water purchased from Promega (Madison, 
W.I., U.S.A.) were used in reverse transcription (RT) reactions. 
For polymerase chain reaction (PCR), dNTP (10 mM each dNTP) and 
magnesium chloride (MgCb； Roche Diagnostics, Mannheim, G.E.R.)； Tag DNA 
polymerase (5 U/),L1; Promega, Madison, W.I., U . S . A . ) were used. Specific sense and 
antisense primers were designed on the basis of previous published data or using 
information obtained from NCBI (Table 2.1). All primers were synthesized by Tech 
Dragon (H.K.S.A.R., China) or Invitrogen (Carlsbad, C.A., U.S.A.). The lyophilized 
primers were reconstituted with Tris-ethylenediaminetetraacetic acid disodiiim salt 
(TE) buffer containing 10 mM of Tris (pH 8.0) and 1 mM of EDTA, to make a stock 
concentration of 100 |j.M. The 10 |iM working solution was prepared by ten-fold > 
dilution of the stock solution with TE buffer. Both stock and working primer solutions 
were stored at -20^C until use. 
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Sense/ Size Tm Gene Primer Sequences (5，to 3，） Antisense (bp) (°C) 
Sense GTTCTTCGACATCACGGCTGAT Pi3ia 409 60 ^ Antisense CATGGCTTCCACAATGCTCATG 
Sense TCAGCCTCTTCTCATTCCTGC T N F a 203 66 Antisense TTGGTGGTTTGCTACGACGTG 
Sense CTAAGAACTACTTCACATCCGCAGC I L - l a 623 55 Antisense CTGGAATAAAACCCACTGAGGTAGG 
Sense CCTTCTTTTCCTTCATCTTTG IL-IB 372 55 Antisense ACCGCTTTTCCATCTTCTTCT 
Sense AAGAAAGACAAAGCCAGAGTC IL-6 263 60 Antisense CACAAACTGATATGCTTAGGC 
Sense GAGTTCAAGGACGGGATGAA • GLT-1 203 60 Antisense GCGATGATCTTCCCACAGAT 
Sense CCACGGATGACATCACACTC GLAST 227 60 Antisense CACGGGTTTCTCTGGTTCAT 
Sense ATGGAGCCCAGCAGCAAGAAGGTGACG Glutl 1478 65 Antisense TCACACTTGGGAGTCAGCCCCCAGAGG 
Table 2.1 Sequences of specific primers used in this study. 
The 6x DNA loading dye was prepared by mixing 30% (v/v) glycerol, 9.25% 
(w/v) bromophenol blue and 36 mM of EDTA (pH 8.5). The 5x Tris-boric-EDTA 
(TBE) buffer was prepared by dissolving 54 g of Tris, 27.5 g of boric acid and 3.72 g 
of EDTA in one litre of NANOpure water, and the pH was adjusted to 8.3. The 
working 0.5x TBE buffer was prepared by a ten-fold dilution of the stock solution. 
The 100 bp DNA ladder marker from Invitrogen (Carlsbad, C.A., U.S.A.) while the 1 
kb DNA ladder marker was purchased from Fermentas (Hanover, M.D., U.S.A.). The 
working solution was prepared by mixing the DNA marker stock, 6x loading dye and 
autoclaved NANOpure water in the ratio of 1:1:4, and was kept at 4°C. Different 
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percentages of agarose gel were prepared by dissolving appropriate amounts of 
agarose (Sigma, St. Louis, M.O., U.S.A.) in 0.5% TBE buffer. Ethidium bromide 
(EtBr) used for gel staining was purchased from Bio-Rad Laboratories (Hercules, 
C.A., U.S.A.). An 10 |ag/ml working solution was prepared by a ten-fold dilution of 
the stock solution. 
2.1.5 Reagents for the Determination of Protein Expressions 
The lOx PBS was prepared by dissolving 80 g of sodium chloride (NaCl), 2 g of 
potassium chloride (KCl), 14.4 g of dibasic sodium phosphate, 2.4 g of monobasic 
potassium phosphate in one litre of NANOpure water. All the above chemicals were 
purchased from Sigma (St. Louis, M.O., U.S.A.). Radioimmunoprecipitation (RlPA) 
buffer was prepared by mixing 1% (v/v) Nonidet P-40 (Promega, Madison, W.I., 
U.S.A.), 0.5% (w/v) sodium deoxycholate (Sigma, St. Louis, M.O., U.S.A.) and 1% 
(w/v) sodium dodecyl sulfate (SDS; Sigma, St. Louis, M.O., U.S.A.) in sterilized Ix 
PBS. Proteasei inhibitor was freshly prepared by dissolving one complete, mini, 
T 
EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics, Mannheim, G.E.R.) 
in 10 ml of RIPA buffer. Phenylmethylsulfonyl fluoride (PMSF) was purchased from 
Sigma (St. Louis, M.O., U.S.A.). 
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The Detergent Compatible (DC) protein assay kit (Bio-Rad Laboratories, 
Hercules, C.A., U.S.A.), which contains alkaline copper tartrate solution, dilute folin 
reagent and surfactant solution, was used in protein determinations. The bovine serum 
albumin (BSA) standard (Sigma, St. Louis, M.O., U.S.A.) was prepared as 1 mg/ml 
stock and was stored as 0.5 ml aliquots at -20°C until use. 
Components for different percentages of SDS-polyacrylamide gel include 30% 
acrylamide/bis solution, 29:1 (Bio-Rad Laboratories, Hercules, C.A., U.S.A.), freshly 
prepared 10% ammonium persulfate (APS; USBiological, Swampscott, M.A., U.S.A.), 
N,N,N',N'-tetra-methylethylenediamine (TEMED; Bio-Rad Laboratories, Hercules, 
C.A., U.S.A.), stacking gel buffer which was prepared by mixing 0.4% SDS with 0.5 
M of Tris hydrochloride (Tris-HCl, pH 6.8), and running gel buffer which was 
prepared by mixing 0.4% SDS with 1.5 M of Tris-HCl (pH 8.8). 
4x SDS gel loading buffer was prepared by mixing 0.8 ml of 0.05% (w/v) 
bromophenol blue, 1 ml of 0.5 M Tris-HCl (pH 6.8), 1.6 ml of glycerol, 1.6 ml of 
20% (w/v) SDS, 3.8 ml of double distilled water and 0.3 ml of p-mercaptoethanol 
(Bio-Rad Laboratories, Hercules, C.A., U.S.A.). The buffer was stored at -20°C until 
» 
use. The working prestained broad range SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) standards (Bio-Rad Laboratories, Hercules, C.A., U.S.A.) was prepared 
in 33% (v/v) glycerol, 3% SDS, 10 mM of Tris (pH 7), 10 mM of DTT, 2 mM of 
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EDTA and 0.01% sodium azide, and was stored at -20°C until use. 
The lOx Tris-glycine-SDS electrophoresis buffer was prepared by mixing 0.25 
M of Tris-HCl (pH 8.3), 1.92 M of glycine and 1% SDS in one litre of NANOpure 
water. The Ix working buffer solution was prepared by a ten-fold dilution of the lOx 
stock solution. 
Coomassie blue staining solution was prepared by dissolving 0.25 g of 
Coomassie R-250 (GE. Healthcare, Buckinghamshire, U.K.) in 10 ml of glacial acetic 
acid, 50 ml of methanol and 50 ml of NANOpure water. The destaining solution was 
prepared by mixing glacial acetic acid, methanol and NANOpure water in the ratio of 
1:3:10. 
lOx Tris-glycine transfer buffer was prepared by mixing 0.25 M of Tris and 1.9 
M of glycine with one litre of NANOpure water. The Ix working transfer buffer was 
freshly prepared by mixing 10% lOx stock solution and 10% methanol in NANOpure 
water. The PolyScreen® PVDF hybridization transfer membrane was purchased from 
PerkinElmer (Boston, M.A., U.S.A.). 
lOx Tris-buffered saline (TBS) was prepared by mixing 0.2 M of Tris, 1.37 M of 
NaCl, and 38 ml of 1 M hydrochloric acid, and the pH value was adjusted to 7.6. The 
washing buffer was prepared by mixing 10% lOx TBS stock solution and 0.1% (v/v) 
Tween®20 (Sigma, St. Louis, M.O., U.S.A.) in NANOpure water. The blocking 
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solution contains 5% (w/v) non-fat milk powder dissolved in the washing buffer. 
Primary and secondary antibodies were purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, C.A. U.S.A.), Abeam (Cambridge, U.K.), Chemicon 
International (Temecula, C.A., U.S.A.) and Cell Signaling Technology (Danvers, 
M.A., U.S.A.), and they were stored at 4°C or -20"C until use. The working solution 
was prepared by freshly diluting the stocks with blocking solution. The details and the 
optimized conditions were shown in Table 2.2. 
The electrogenerated chemiluminescence (ECL) detection kit was purchased 
from G.E. Healthcare (Buckinghamshire, U.K.), and it was stored as aliquots at 
Primary Antibody (Dilution) Secondary Antibody (Dilution) Size (kDa) 
Rabbit polyclonal GLT-1 (1:1000) Anti-rabbit 1:2000 62 
Rabbit polyclonal GLAST (1:1000) Anti-rabbit 1:2000 62 
Rabbit polyclonal 
Anti-rabbit 1:2000 42,44 
p44/42 MAPK (1:1000) 
Mouse monoclonal 
Anti-mouse 1:2000 42,44 phospho-p44/42 MAPK (1:1000) Mouse monoclonal elyceraldehyde ^ Anti-mouse 1:5000 38 3-phosphate dehydrogenase (1:10000) 
Table 2.2 The dilutions of the primary and secondary antibodies. 
> 
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2.1.6 Reagents for Functional Assays 
2.1.6.1 Reasents for Enzyme-Linked Immunosorbent Assay (ELISA) of IL-6 
The Biotrak'^ rat IL-6 ELISA kit was purchased from G.E. Healthcare 
(Buckinghamshire, U.K.). 
2.1.6.2 Reasents for Glutamate Uptake Assay 
L-[G-^H]Glutamic acid solution (1 mCi/ml) was obtained from GE. Healthcare 
(Buckinghamshire, U.K.) and the scintillation cocktail was from PerkinElmer (Boston, 
M.A., U.S.A.). HEPES-buffered Krebs-Ringer (HBKR) solution was prepared by 
dissolving 156 mM of NaCl,-5.6 of mM KCl, 11 mM of NaHCOs, 10 mM of 
D-glucose, 1 mM of magnesium sulphate, 1 mM of calcium chloride, 1 mM of 
monobasic sodium phosphate and 20 mM of HEPES-Na in 1 litre of NANO-pure 
water, and the pH was adjusted to 7.4. 
2.1.6.3 Reasents for Extracellular Glutamate Determination Assay 
One ml of the substrate mixture for the glutamate clearance assay was prepared 
by firstly mixing 20 U of glutamate dehydrogenase from beef liver (E.C. 1.4.1.3) and 
2.5 mg/ml of P-nicotinamide adenine dinucleotide with 0.2 M of Tris-HCl buffer (pH 
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8.2) containing 0.1% (v/v) Triton® X-100. Then, 0.25 mg/ml 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, pH 7.4) and 100 
jiM of 1 -methoxyphenazine methosulfate (pH 7.4) were added. The uptake reaction 
was terminated by the addition of a stop solution composing of 50% 
dimethyl fonn amide and 20% SDS (pH 4.7). L-Glutamate and glutamate 
dehydrogenase were purchased from Wako Pure Chemical Industries Ltd. (Osaka, 
Japan); whereas other chemicals were purchased from Sigma (St. Louis, M.O., 
U . S . A . ) . 
2.1.6.4 Reasents for Glucose Uptake Assay 
2-^H-deoxyglucose (2-^H-DOG) (1 mCi/ml) was purchased from GE. 
Healthcare (Buckinghamshire, U.K.)- 0.1 mM of 2-deoxyglucose (2-DOG) was 
prepared by dissolving 2-DOG (Sigma, St. Louis, M.O., U.S.A.) in autoclaved water. 
100 mM of phloretin solution, which was used to terminate glucose uptake, was 
freshly prepared by dissolving the phloretin powder (Sigma, St. Louis, M.O., U.S.A.) 
in absolute ethanol. All of the above reagents were stored at 4°C until use. > 
2.1.6.5 Reasents for MTT Assay 
MTT (Sigma, St. Louis, M.O., U.S.A.) was diluted to 5 mg/ml with Ix PBS. 
34 
After filtering through an 0.22 |am filter (Millipore, Billerica, M.A., U.S.A.), the stock 
solution was covered with an aluminum foil and was stored at 4°C until use. 
2.1.6.6 Reasents for GFAP Immunostciinins 
Microscope cover glasses and microscope slides (Fisher Scientific, Pittsburgh, 
P.A., U.S.A.) were sterilized before use. Paraformaldehyde (PFA; Sigma, St. Louis, 
M.O., U.S.A.) was dissolved in hot Ix PBS and was passed through a 0.22 |im filter 
(Millipore, Billerica, M.A., U.S.A.) before use. The blocking solution was made up of 
5% FBS in Ix PBS. Propidium iodide (PI) purchased from Sigma (St. Louis, M.O., 
U.S.A.) was dissolved in Ix PBS. All reagents were stored at 4°C before use. 
PBS-Tween®20 (PBS-T) was prepared by mixing 0.05% (v/v) Tween®20 in Ix PBS. 
The goat anti-GFAP primary antibody was purchased from Santa Cruz Biotechnology 
Inc. (Santa Cruz, C.A., U.S.A.), and it was used in a dilution of 1:500 in PBS-T. The 
fluorescein isothiocyanate (FITC)-conjugated mouse anti-go at secondary antibody 
was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, C.A., U.S.A.), and it 
was used in a dilution of 1:1000 in PBS-T. > 
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2.2 Methods 
2.2.1 Preparation of Primary Astrocytes 
Astrocytes were directly isolated from the cerebral cortex of two-day-old SD 
rats as described in Chang et. al. (2001). SD rats were decapitated and the cerebral 
cortices were isolated under a dissection microscope. The cortices were cut into 1 
mm^ pieces under aseptic conditions then trypsinized with 0.25% trypsin-EDTA at 
37"C for 15 minutes. After centrifuging at 1,800 g for 5 minutes and ceasing 
trypsinization with FBS (trypsin:FBS = 1:1), the pellets were dispersed with a 19 
gauge needle and the suspension was allowed to pass through a 70 fim nylon mesh 
(Spectrum Laboratories Inc., Rancho Dominguez, C.A., U.S.A.). Then, cells were 
evenly seeded in 75 cm^ culture flasks, and were incubated in a 3 7 V incubator 
supplemented with 5%/95% C02/air. The medium was changed after two days and 
subsequently three times a week. After the culture reached confluence which was 
about 7-10 days later, it was shaken at 180 rpm at 3 T C on an orbital shaker for 16 
T 
hours to remove other cell types including oligodendrocytes and microglia (McCarthy 
and de Veil is, 1980). The cells were then trpysinized with 0.25% trypsin-EDTA and 
seeded at different densities for various experiments. The purity of the culture was 
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determined from GFAP immunostainning (Chang et. al., 2001) and was found to be 
greater than 90%. 
2.2.2 Determination of Gene Expressions by Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) 
After the cells were subjected to different treatments, total RNA was extracted 
according to the procedures described by Lung et. al. (2005). The culture medium was 
aspirated and the cells washed with ice-cold PBS for two times. The cells were then 
incubated in 1 ml of TRIzol reagent for 5 minutes at room temperature. After scraping 
with a cell scraper, the cell lysates were transferred to a microfuge tube containing 0.2 
ml of chloroform. The cell lysate and the chloroform were thoroughly mixed by 
vortex for 15 seconds, and the mixture was allowed to stand for 2 minutes at room 
temperature followed by centrifugation at 11,900 g for 15 minutes at 4°C. After 
centrifugation, the upper clear aqueous layer containing the RNA was carefully 
transferred, without disturbing the lower layers, to a new microfuge tube. 0.5 ml of > 
isopropanol was then added to the aqueous layer to precipitate the RNA at -20®C for 
24 hours. The precipitated RNA was obtained by centrifugation at 11,900 g for 15 
minutes at 4()C. After aspirating the isopropanol, 1 ml of 75% ethanol was added to 
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wash the pellet. Then, it was centrifuged at 7,500 g for 20 minutes at 4°C. The ethanol 
was aspirated completely, and the pellet was allowed to dry in the tissue culture 
cabinet. The RNA was finally dissolved in appropriate amount of nuclease-free water, 
and was stored at -20"C until use. 
The concentrations of RNA samples were determined using a 
spectrophotometric method. By measuring the absorbance at 260 nm and 280 nm with 
a spectrophotometer, the concentration and purity of the RNA samples were 
calculated. An absorbance at 260 nm of one unit is approximately equivalent to 40 
|Lig/inl of RNA. The ratio of the absorbances at 260 nm to 280 nm represents the 
purity of the RNA samples, and only RNA samples with a ratio range of 1.7 to 2.0 
were used for the RT-PCR experiments. The RNA samples were incubated at 65®C for 
20 minutes prior to RNA concentration determination. 
RNA gel electrophoresis was performed to determine the integrity of the RNA 
samples. The RNA samples were first diluted to 0.5 |ig/ml. Then, they were separated 
by 1% (w/v) agarose gel in 0.5x TBE buffer. Two dominant bands representing the 
18S (~2 kb) and 28S ( � 5 kb) ribosomal RNA were observed. The integrity of the > 
RNA was determined by the intensity of the bands in which the 28S RNA band is 
approximately doubled to that of the 18S RNA band. 
Reverse transcription was performed according to the protocol provided by the 
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superscript '^-11 Reverse Transcriptase (Invitrogen, Carlsbad, C.A., U.S.A.). Briefly, 
1 |ag of RNA sample was mixed with 2 of dNTPs and 2 of random primer, and it 
was made up to 12 |li1 with nuclease-free water. The mixture was then heated at 65"C 
in a PGR machine (GeneAmp PGR system 9700, PerkinElmer, Boston, M.A., U.S.A.) 
for 5 minutes, then immediately chilled on ice. In the mean time, reaction mixture 
containing 4 of 5x First-Strand buffer, 2 |al of DTT and 1 |il of RNase inhibitor was 
prepared and heated at 4 2 � C for 2 minutes. 1 f l^ of SuperScript^"^-!! reverse 
transcriptase was added to the reaction mixture afterwards, and they were mixed with 
the chilled sample mixture. The reaction mixture containing a total volume of 20 
was then incubated at 25"C for 10 minutes, 42°C for 50 minutes, 70°C for 15 minutes 
and 4"C for 10 minutes in a PCR machine. The complementary DNA (cDNA) was 
stored at -20°C until used. 
PCR reaction mixture was prepared by mixing 2.5 of lOx PCR buffer, 2.5 
of MgCh, 1 of each sense and antisense primers, 0.5 |al of dNTP mix, 0.2 jil of Tacj 
DNA polymerase and 1.5 of cDNA sample. The mixture was then incubated in a 
PCR machine using the PCR conditions of 94°C for 5 minutes, and 16 to 40 cycles of 
I 
94°C for 30 seconds, 55 to 6 6 � C for 1 minute and 7 2 � C for 1 minute, followed by 
7 2 � C for 5 minutes. The PCR products were stored at - 2 0 � C until used. 
In order to quantify the amount of target gene in the PCR products, DNA gel 
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electrophoresis was performed. The PCR products were mixed with the 6x DNA 
loading dye and were separated by 1.5% agarose gel in 0.5x TBE buffer. 100 bp or 1 
kb DNA ladder was added for the determination of the target bands. After gel 
electrophoresis, the gel was stained with 1 |ag/ml EtBr and destained with distilled 
water. 
2.2.3 Determination of Protein Expressions by Western Blotting 
Total protein in cultured cells was extracted according to the following 
procedures. Firstly, the culture medium was discarded, followed by washing with 6 ml 
of ice-cold PBS. 1 ml of freshly prepared RIPA buffer containing protease inhibitor 
was added to lyse the cell for 5 minutes. After scraping, the cell lysates were 
transferred to a microfuge tube. Ten |j,l of PMSF was added and the mixture was 
chilled on ice for an hour. The mixture was then centrifuged at 10,000 g for 10 
minutes at and the supernatant was transferred to a new microfuge tube. The 
protein sample was concentrated to about 100 f l^ by the Savant Speed Vac Systems 
(Global Medical Instrumentation Inc., Minneapolis, M.N., U.S.A.). The concentrated 
samples were stored at 4"C until used. 
The concentrations of the protein samples were determined using the DC protein 
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assay kit. In brief, the protein samples was firstly diluted with Ix PBS. Then, the 
diluted protein with a total volume of 12.5 was mixed with 62.5 of freshly 
prepared reaction mixture containing 2% Reagent S and 98% Reagent A. 0.5 ml of 
Reagent B was then added and incubated at room temperature for 15 minutes in 
darkness. Absorbance at 750 nm was mearsured with the reaction mixture containing 
no protein which served as the blank. A standard curve was generated using different 
concentrations of BSA (0.2 mg/ml, 0.4 mg/ml, 0.6 mg/ml, 0.8 mg/ml and 1.0 mg/ml) 
instead of protein samples, and the concentration of the protein in each sample was 
calculated from the standard curve. 
The protein samples were then diluted with autoclaved water, and mixed with 
25% (v/v) 4x SDS gel loading buffer. The samples were heated at 99"C for 3 minutes. 
The proteins in the samples were separated by the SDS-polyacrylamide gel, and the 
components for casting a 12% gel have been shown in Table 2.3. The gel was then 
immersed into Ix electrophoresis buffer. Protein samples, together with the prestained 
SDS-PAGE standard, were then loaded into the gel, and were run at lOOV for 2 hours. 
> 
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Reagents 12% Separating Gel 5% Stacking Gel 
Bis-acryiamide 30 % Aj^ 0.825 ml 
Running Gel Buffer 2.5 ml — 
Stacking Gel Buffer --- 1.25 ml 
Autoclaved Water 3.4 ml 2.875 ml 
^ 100 |il 50 1^ 1 
T E M E D 6.6 |al 3.3 i^l 
Table 2.3 Components used in casting 5% and 12% SDS polyacrylamide gels 
The separated proteins on the polyacrylamide gel were transferred to a 
PolyScreen® PVDF hybridization transfer membrane, pre-wetted with methanol. The 
transfer was performed at 1OOV for 2 hours. 
The membrane was then incubated in 5% non-fat milk in TBS-T to block the 
non-specific binding site. One hour later, the membrane was rinsed briefly with 
TBS-T and incubated with primary antibodies for 2 hours at room temperature. The 
membrane was then washed with TBS-T for 4 times, each for 15 minutes. Secondary 
antibodies were added and incubated for 1 hour at room temperature. After another 10 
minute-wash with TBS-T for 4 times, the membrane was taken for ECL detection. 
The membrane was evenly incubated with equal volumes of ECL™ detection reagent 
mixture for one minute. After removing excessive reagents, an X-ray film was > 
allowed to expose to the treated-membrane in darkness for various time intervals, and 
the immunoreactive bands were visualized on the film. 
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2.2.4 ELISA 
ELISA was performed according to the protocol provided in the Biotrak"^ rat 
lL-6 ELISA kit at room temperature. Culture medium was centrifiigated at 1,000 g for 
3 minutes to remove cell debris prior to storage at -20"C. Firstly, 50 \i\ of sample 
diluent was added to all wells of an 96-well ELISA plate pre-coated with the anti-rat 
IL-6 antibody. Then, 50 |al of prepared samples, or IL-6 standards in different 
concentrations, were added and allowed to react with the antibody for 2 hours. After 
washing the wells 3 times with the washing buffer, 100 |il of pre-mixed biotinylated 
antibody reagent was added to each well and further incubated for an hour. The wells 
were then washed with washing buffer for 3 times, then incubated with 100 |al of 
horse radish peroxidase streptavidin conjugate reagent for 30 minutes. 100 of 3.3', 
5.5'-tetramethylbenzidine (TMB) substrate was added to start the reaction. After 30 
minutes of incubation, 100 \i\ of stop solution was added and the absorbance at 450 
nm was measured using an ELISA plate reader (Bio-Rad Laboratories, Hercules, C.A., 
U.S.A.) within 30 minutes. A standard curve was constructed using different > 
concentrations of IL-6 (31 pg/ml, 62 pg/ml, 125 pg/ml, 250 pg/ml, 500 pg/ml, 1000 
pg/ml and 2000 pg/ml), and the concentrations of IL-6 in the samples were calculated 
from the standard curve. 
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2.2.5 Glutamate Uptake Assay 
This assay was described by Han et. al. (2004) with slight modifications. Briefly, 
cultures were first placed in 4"C refrigerator for 5 minutes. After the removal of 
growth medium, cells were washed once with ice-cold HBKR buffer, then 1 |aCi/ml 
of L-[G-^H]glutamic acid in ice-cold HBKR buffer was added and the cells were 
incubated at 1)TC for 2 minutes. After incubation, the medium was quickly removed 
and the cells were washed three times with ice-cold HBKR buffer, then lysed with 1 
ml of 1 M NaOH. 400 of the lysate was taken for scintillation counting. The 
remaining fraction was used for protein determination as described in Section 2.2.3, 
except that the BSA standard stock solution was dissolved in IM NaOH instead. 
2.2.6 Extracellular Glutamate Determination Assay 
This assay is based on the principle that glutamate, in the presence of glutamate 
dehydrogenase, will drive a series of redox reactions, and finally convert the yellow 
» 
MTT into purple MTT formazan (Abe et. al., 2000). By determining the intensity of 
the final product spectrophotometrically, the concentration of glutamate can be 
estimated. Briefly, 50 of culture medium were first transferred to a 96-well 
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mi crop late, and then mixed with 50 |jJ of substrate mixture prepared as in Section 
2.1.6.3. The mixture was incubated at 3TC for 10 minutes, then 100 |al of stop 
solution was added to terminate the reaction, then the absorbance was measured at 
540 nm. A standard curve was constructed using culture media containing known 
concentrations of L-glutamate. The concentration of glutamate in the samples was 
determined from the standard curve. 
2.2.7 Glucose Uptake 
After drug treatment for 24 hours, cells were first washed with warm Ix PBS, 
then 500 |al of Hanks buffer (HSB) were added to fast the cells for an hour. After 
fasting, the cells were incubated with a mixture containing 0.1 mM of 2-DOG and 1 
jtiCi of 2-^H-DOG in HSB for an hour. The uptake reaction was stopped by placing on 
ice followed by the addition of 0.3 mM of phloretin. The cells were washed twice 
with 0.3 mM of phloretin, and lysed with 0.5% SDS. 200 ul of the lysate was taken 
for scintillation counting, while the remaining portion was subjected to total protein 
> 
determination by DC protein assay. 
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2.2.8 MTT Assay 
MTT assay was performed according to the procedure described by Lung et. al.’ 
(2005). Briefly, different concentrations of drugs were added to cells seeded in a 
96-well microtiter plate for 24 hours. After a 24-hour incubation with the drugs, 30 
of MTT solution was added to each well, and incubated at YTC for 2 hours, then the 
medium was removed by suction and 100 of absolute DMSO was pipetted into 
each well. The plate was immediately covered with a piece of aluminum foil and 
shaken on a plate shaker (Lab-Line Instruments Inc., Melrose Park, I.L., U.S.A.) for 
15 minutes. The absorbance at 540nm was determined using a microplate reader 
(Bio-Rad Laboratories, Hercules, C.A., U.S.A.) with DMSO as the blank. 
2.2.9 GFAP Immunostainina： 
Astrocytes were grown to 50% confluence on a microscope cover glass, washed 
twice with ice-cold PBS, then fixed with 2% PFA solution for an hour. Upon the 
* 
removal of PFA solution, cells were washed with ice-cold PBS twice, then 
permeabilized with 1% Triton X-100 solution for 5 minutes, followed by 3 times of 
ice-cold PBS wash. The cells were then blocked with 5% FBS for 1 hour, and washed 
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with ice-cold PBS 3 times. The nuclei were stained with 1 mg/ml of PI for 1 hour in 
darkness. Excessive PI solution was removed by washing the cells with ice-cold PBS 
for 3 times. The cells were then probed with anti-GFAP antibody (1:500 in PBS-T) for 
24 hours in darkness. Then the cells were washed with PBS-T for 3 times followed by 
probing with FITC-conjugated secondary antibody (1 :1000 in PBS-T) for 1 hour. 
Finally, the cover glasses were washed with PBS-T for 3 times and PBS once, and 
mounted and photos were taken with a Leica non-linear laser confocal microscope 
(Leica Microsystems, Wetzlar, GE.R.). 
2.2.10 Band Intensity Quantification 
For RT-PCR and western blot analysis, the intensities of the bands were 
quantified using the I mage J image processing program (inspired by NIH Image for 
the Macintosh). 
2.2.11 Statistical Analysis 
* 
All experiments were performed at least three times to determine the statistical 
significance. Statistical difference was determined using Kruskal-Wallis Analysis of 
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Variance (ANOVA) on ranks (Dunnett's post-test) or Student's t-Test in the 
SigmaStat program (S.P.S.S. Inc., Chicago, I.L., U.S.A.). Samples treated with 3 mM 
glucose in all experiments serve as the control. Data of 1 or 2 mM glucose-treated 
groups was normalized with the control. Multiple comparisons were performed 
against the control and significance was shown when the p-value is less than 0.05. 
> 
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CHAPTER 3 RESULTS 
3.1 Preparation of Primary Astrocyte Culture 
During the course of astrocyte isolation from the cortex, it is inevitably that 
other cell types, for example oligodendrocytes and microglia, would be present in the 
culture. In order to ensure the results obtained were mainly the effects on astrocytes, a 
high purity (>90%) of astrocyte culture (Lin et. al., 2002) had to be maintained. A 
greater growth rate of astrocytes over other cell types as well as the 16-hour shaking 
of the culture at 180 rpm was able to remove oligodendrocytes and microglia 
effectively (McCarthy and de Vellis, 1980). After shaking, astrocytes were plated in 
6-well plates containing a piece of microscope cover glass. After the culture was 
grown to 50% confluence, we fixed the cells and performed GFAP immunostaining 
together with PI staining. As seen under a confocal microscope, more than 90% of the 





Total Number of Total Number of Percentage of 
Pl-positive Cells GFAP-positive Cells GFAP-positive Cells 
^ m 91.6% 
Figure 3.1 A high purity of the astrocyte culture shown by GFAP 
immunostaining. 5 X lO* cells/ml cells were seeded in each well of a 6-well plate. 
After the culture reached 50% confluence, the cells were fixed and stained with 
GFAP and PI as described in Section 2.2. The GFAP immunostaining representing 
the astrocytes was shown in green (A) whereas the PI staining representing the 
nuclei was shown in red (B). The merged image of the GFAP stain and PI stain was 
shown in (C). The table showed the percentage of GFAP-positive cells against the 
total number of Pl-positive cells. The numbers are counted from 5 individual 
confocal microscopic pictures. 
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3.2 Effects of Glucose Deficiency on Astrocyte-mediated Glutamate Uptake 
Due to the impaired Glutl function in Glutl DS patients, glucose transported 
across the BBB into the brain decreases, leading to a prolonged reduction of glucose 
supply to brain cells. Clinically, epilepsy tends to occur at high frequency. An 
understanding of the etiology of the epilepsy is essential to improve their symptoms. 
Glutamate accumulation at the synapse was believed to be one cause of seizure. 
Therefore, in the first part of my project, I investigated the relationship between 
prolonged glucose deficiency and the function of the glutamate uptake system in 
astrocytes. 
3.2.1 Effects of Glucose Deficiency on the Expressions of Glutamate Transporters 
Two glutamate transporters namely GLT-1 and GLAST are found to express in 
astrocytes (Gegelashvili and Schousboe, 1997). As they are essential in the process of 
glutamate clearance from the extracellular spaces, we first determined the gene and 
» 
protein expressions of these two major transporters upon glucose deficiency. 
After the culture has reached 80% confluence, medium containing 0.1% FBS 
was added to synchronize the cells for 48 hours. Then, the cells were treated with 
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various glucose concentrations (1 to 3 mM). As the CSF glucose level is around 2.7 
mM, the 3 mM treated-group in the experiments represented the physiological 
condition. 1 mM and 2 mM glucose in the treatment represented the glucose deficient 
conditions. In order to attain a chronic effect, the treatment lasted for 5 days in which 
the medium was changed on day 3. Afterwards, total RNA and total protein were 
being extracted and the expression levels were determined by RT-PCR and western 
blotting respectively. 
As shown in Figure 3.2, as the glucose concentration decreased, a significant 
reduction in the mRNA expression (p<0.05) and a decreasing trend in the protein 
expression were observed for GLT-1, but not GLAST. The results suggested that upon 
prolonged glucose deficiency, astrocytes adapted by reducing glutamate transporter 
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Figure 3.2 Prolonged glucose deficiency altered the gene and protein expressions 
of the major glutamate transporters in primary astrocytes. After the astrocyte 
culture were synchronized with 0.1% FBS for 48 hours, the cells were treated with 
different glucose concentrations (1-3 mM). Total RNA and protein were extracted 5 
days after treatment as described in Section 2.2. RT-PCR and western blotting were 
performed to determine the gene and protein expressions of GLT-1 (A-B) and GLAST 
(C-D). Cells incubated in the presence of 3 mM glucose was taken to unity and served 
as control. Ppia (peptidylprolyl isomerase A) which is a cytosolic protein found in 
cells including glial cells was used as the internal control. Results represent the mean 
土 S.E. of three independent experiments. The lane “M” represents 100 bp marker. “*” 
signifies significant difference (p<0.05) by ANOVA on Ranks (Dunnett's post-test) 
when compared with the control. 
> 
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3.2.2 Effects of Glucose Deficiency on Glutamate Uptake in Primary Astrocytes 
At the synapse, excessive glutamate in the extracellular space is taken up into 
astrocytes via glutamate transporters. Previous data revealed the effects of glucose 
deficiency on the reduction of GLT-1 expression, we next determined whether the 
change of GLT-1 expression incur any effect on the glutamate transport function. 
Two approaches were adopted to examine the glutamate uptake mechanism in 
astrocytes. By introducing radioactive-labeled glutamate into the media, we can 
determine the amount of labeled glutamate being taken up by astrocytes. On the other 
hand, through a series of redox reactions, the concentration of glutamate remained in 
the media after the uptake process can be determined colorimetrically by the 
glutamate clearance assay (Abe et. al., 2000). 
Unexpectedly, from the result of radioactive glutamate uptake, we did not find 
significant difference among the three groups treated with different glucose 
concentrations (Figure 3.3A). The uptake of radioactive-labeled glutamate was 
restricted in 2 minutes. This is to ensure the process was within the linear region 
* 
(Figure 3.3B). Besides, the conversion of the radioactive glutamate into other 
metabolites was minimized. The above results suggested that after prolonged glucose 
deficiency, the reduction in GLT-1 expression did not contribute significantly to a 
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change in the glutamate uptake in primary astrocytes. In addition, the glutamate 
clearance curve among the treated samples showed no obivous difference (Figure 
3.4C). The degradation curve shown confirmed that the gradual decrease of 
extracellular glutamate concentration was not due to the natural degradation of 
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Figure 3.3 Prolonged glucose deficiency exerted no effect on glutamate uptake in 
primary astrocytes. Astrocytes (50,000 cells/ml) were allowed to grow to 80% 
confluence in 6-well plates. After synchronizing the cells for 48 hours, the cells were 
treated with different glucose concentrations for 5 days. Then, the cells were 
subjected for glutamate uptake assay with the addition of radioactive glutamate. Cells 
incubated in the presence of 3 mM glucose was taken to unity and served as control. 
Results shown represent the 土 S.E. of three independent experiments. Significant 
difference was determined by ANOVA on Ranks when compared with the control (A). 
Cells incubated in radioactive glutamate were taken for radioactive counting at 
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Figure 3.4 Effect of glucose deficiency on glutamate clearance in primary 
astrocytes. After synchronization for 48 hours and treatement for 5 days, astrocytes 
(initial seeding density: 50,000 cells/ml) were allowed to take up the externally added 
glutamate. At different time intervals, the medium was taken out for glutamate 
clearance assay as described in Section 2.2.13. Concentrations of extracellular 
glutamate was calculated from the stardard curve constructed using known 
concentrations of glutamate (A). A degradation curve was constructed by performing 
the experiment with no astrocytes to ensure no natural degradation of glutamate 
occured (B). Results shown (C) represent the 士 S.E. of three independent experiments 
in duplicate setup (n=6). Significant difference was determined by AN OVA on Ranks 
when compared with the control (3 mM). 
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3.3 Astrocytic Glucose Transport under Glucose Deficiency 
The unexpected results of glutamate uptake upon prolonged glucose deficiency 
implied that other mechanisms may be activated to compensate for the reduction of 
glutamate transporter expression. Glutamate uptake is coupled to the entry of sodium 
ions, which in turn depends on energy provided by glucose metabolism. Thus, energy 
availability in astrocytes may be a critical factor controling the glutamate uptake 
mechanism. 
As glucose is the major source for energy production in astrocytes, we first 
examined whether there was any change in the expression of Glutl upon glucose 
deficiency. From Figure 3.5, though no statistical difference was detected using 
ANOVA on Ranks, we observed an increasing expression in Glutl gene when the 
glucose concentration dropped from 3 mM to 1 mM. With the upregulation in Glutl 
expression, we suspected an increase in glucose uptake in astrocytes. By externally 
introducing radioactive-labeled glucose, we found that, after prolonged glucose 
deficiency, a significant increase in glucose uptake was shown in astrocytes (p<0.05; 
Figure 3.6), implying that the glucose availability as well as the energy production 
may increase accordingly. 
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Figure 3.5 Glucose deficiency induced an upregulation of Glutl gene in primary 
astrocytes. Upon 80% confluence of the astrocyte culture, the cells were 
synchronized and treated with different glucose concentrations (1-3 mM) for 5 days. 
Total RNA was extrated and RT-PCR was performed to determine the Glutl gene 
expression. Cells incubated in the presence of 3 mM glucose was taken to unity and 
served as control. Results shown represent the 土 S.E. of three independent 
experiments. Significant differences were determined by ANOVA on Ranks when 
compared with the control (3 mM). 
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Figure 3.6 Glucose deficiency induced an increase in glucose uptake in primary 
astrocytes. Upon 80% confluence of the astrocyte culture, the cells were 
synchronized and treated with different glucose concentrations (1-3 mM) for 5 days. 
After discarding the culture medium, the cells were incubated with a mixture 
containing 0.1 mM of 2-DOG and 1 jiCi of2-^H-DOG in HSB for an hour. The lysate 
was taken for scintillationg counting and total protein determination. Cells incubated 
in the presence of 3 mM glucose was taken to unity and served as control. Results 
shown represent the 士 S.E. of three independent experiments in duplicate setup (n=6). 
"*" signifies significant difference (p<0.05) by ANOVA on Ranks (Dunnett's 
post-test) when compared with the control (3 mM). 
> 
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3.3.1 Effects of Glucose Deficiency on the Expressions and Secretion of 
Inflammatory Cytokines 
Previously, Wong (2005) had found the relationship between externally 
supplemented cytokines and glucose uptake. When different inflammatory cytokines, 
including TNFa, IL- la , IL-lp and IL-6, were added to astrocytes incubated in high 
glucose medium (25 mM of glucose), the Glutl protein expressions as well as the 
glucose uptake increased significantly. Thus, we hypothesized that prolonged glucose 
deficiency increased the energy availability in astrocytes mediated by the changes in 
cytokine expressions. 
Firstly, we determined the expression of different cytokines by RT-PCR after a 
5-day treatment. We found that glucose deficiency exerted a cytokine-specific 
induction in which IL - l a showed a significant decrease (p<0.05), IL-6 showed a 
significant increase (p<0.05), whereas TNFa and IL-1 (3 showed no change (Figure 
3.7). 
The significant induction of IL-6 upon glucose deficiency further investigated. 
This is because IL-6 was found to support neuronal survival (De Jongh et. al., 2003). 
Besides, previous findings suggested that exogenous IL-6 exerted the greatest effects 
on Glutl protein expression and glucose uptake among the cytokines tested (Wong, 
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2005). Thus, we further investigated the role of IL-6 in glucose deficient condition. 
Due to the fact that lL-6 is a secretory protein, we determined the amount of 
secreted IL-6 into the medium using ELISA. Throughout the 5 days of treatment, the 
medium was changed on day 3. Samples were collected on day 3 as well as day 5 for 
the ELISA assays. The amount of IL-6 in the media was calculated from the standard 
curve (Figure 3.8A), and we observed a significant increase of IL-6 in the media on 
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Figure 3.7 Expression of different cytokines including A) TNFa ； B) I L - l a ； C) 
IL-lp and D) IL-6 upon glucose deficiency in primary astrocytes. After the 
astrocyte culture were synchronized with 0.1% FBS for 48 hours, the cells were 
treated with different glucose concentrations (1-3 mM). Total RNA was extracted 5 
days after treatment as described in Section 2.2, and RT-PCR was performed to 
determine their gene expressions. Cells incubated in the presence of 3 mM glucose 
was taken to unity and served as control. Ppia (peptidylprolyl isomerase A) which is a 
cytosolic protein found in cells including glial cells was used as the internal control. 
Results shown represent the 土 S.E. of three independent experiments. The lane�‘M’’ 
represents 100 bp marker. ‘‘*,, signifies significant difference (p<0.05) by ANOVA on 









0 ,6 - • 
0.4 - Z 
Q i^— 1 1 1 I I 
0 500 1000 1500 2000 2500 
standard Concentration (pg/ml) 
B) C) 
1 4 1 .4 -
1,2 1.2 • ” 
^ 飞 I T 
" 卜 r ^ ' ' " ^ r i 
I I s" oi - oi -I I I 0.6 - I 0.6 • < < I I 0 , 4 - I 0 . 4 -
0,2 - 0.2 -
0 1 1 1 0 1 1 1 
Imi'l lioM IniM 2JILM 'jjnM 
CIDCOJC CojoDifltriiUciii Cdowac Coacrjit: jtbji 
Figure 3.8 Prolonged glucose deficiency increased the amount of IL-6 secreted 
from primary astrocytes on day 3, but not on day 5. After synchronization, cells 
were treated with different glucose concentrations for 5 days. Media were collected to 
determine the amount of IL-6 secreted by ELISA on day 3 (B) and day 5 (C). The 
actual concentrations were calculated using the standard curve constructed (A). Cells 
incubated in the presence of 3 mM glucose was taken to unity and served as control. 
Results shown represent the 士 S.E. of three independent experiments. ‘‘*，，signifes 
significant difference (p<0.05) by ANOVA on Ranks (Diinnett's post-test) when 
compared with the control (3 mM). 
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3.3.2 Effects of Exogenous Interleukin-6 on Glucose Uptake in Primary Astrocytes 
under Glucose Deficiency 
The observed increase in secreted IL-6 in the extracellular space suggested that 
IL-6 may exert autocrine effects in astrocytes through the binding onto the IL-6 
receptors present on their plasma membrane (Wang et. al, 1992). In order to 
determine the effects of extracellular IL-6 in astrocytes, in terms of energy availability, 
under glucose insufficiency, we added various concentrations of recombinant IL-6 
into the medium to examine its effect on glucose uptake. 
First, we determined the effects of different concentrations of IL-6 to the 
cytotoxicity in astrocytes by MTT assay. The working concentration of recombinant 
IL-6 used in other studies was usually around 10 ng/ml (Hinkerohe et. al., 2005), so 
we used 0 ng/ml, 0.1 ng/ml, 1 ng/ml and 10 ng/ml as the testing concentrations for the 
MTT assay. The result suggested that up to 10 ng/ml IL-6 added, no observable effect 
was detected in the cell survival (Figure 3.9). Thus, in the following experiments, 10 
ng/ml of IL-6 was used as the tested concentration. 
‘ U p o n the addition of radioactive glucose, we determined the effects of 
exogenous IL-6 on the glucose uptake in astrocytes under glucose deficient conditions. 
For astrocytes treated with 2 mM and 3 mM glucose, the addition of 10 ng/ml of 
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recombinant IL-6 increased the glucose uptake significantly (p<0.05). However, for 
cells incubated in 1 mM glucose, the glucose uptake showed no observable change 




1 2 0 ... 
. . . . - . - . . - - I 
100 : . . : : : : — � = m 
1 80 … I 一 -
匕 “ - ' B - - 2mM 




0 ‘ ‘ ‘ ‘ ‘ 
0 2 4 6 8 ‘ 10 
EL-6 Concentration (ng/ml) 
Figure 3.9 Effects of exogenous IL-6 on the cell viability in primary astrocytes. 
Primary astrocytes (5 x lO^ cells/ml) were seeded in a 96-well plates for 24 hours. 
Following the 48-hour synchronization, cells were treated with different glucose 
concentrations (1-3 mM) for 24 hours. After the incubation, MTT assay was 
performed according to the procedures described in Section 2.2. Results shown 
represent the 土 S.E. of three independent experiments in duplicate setup (n=6). 
Statistics were done using ANOVA on Ranks (Dunnett's post-test) with the 
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Figure 3.10 Effects of exogenous IL-6 on the glucose uptake by primary 
astrocytes. Primary astrocytes, upon 80% confluence, were synchronized with 0.1% 
FBS. The cells were treated with different glucose concentrations. On day 4，10 ng/ml 
of IL-6 were introduced to the cells and incubated for 24 hours. After discarding the 
culture medium, the cells were incubated with a mixture containing 0.1 mM of 
2-DOG and 1 jaCi of 2-^H-DOG in HSB for an hour. The lysate was taken for 
scintillationg counting and total protein determination. Results shown represent the 土 
S.E. of three independent experiments in duplicate setup. “*’，signifies significant 




3.4 Signaling Mechanism Mediating the Astrocytic Responses under Glucose 
Deficiency 
Prolonged glucose deficiency triggered a variety of responses in astrocytes. Yet, 
the underlying signaling mechanism regulating these events are not well understood. 
The activation of ERKl/2 pathway was shown to correlate with various biological 
responses which include growth induction (Robinson and Cobb, 1997)，involvement 
in cytokine expressions (Lee et. al., 2000) and reduction of astrocytic glutamate 
transport (Abe and Misawa, 2003). In the present study, we investigated the 
involvement of ERK MAPKs in glucose deficiency-induced glutamate transport using 
a specific inhibitor of the ERK pathway. 
3.4.1 Effects of Glucose Deficiency on the Expressions of Total and Phosphorylated 
ERK 1/2 in Primary Astrocytes 
We first determined the effects of glucose deficiency on the activation of ERK 
» 
MAPKs. Western blotting was performed to examine the protein levels of the total 
and the phosphorylated forms of ERK MAPKs (pERK). From the results, we 
observed that when the glucose concentrations reduced from 3 mM to 2 and 1 mM, 
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the expressions of total ERKl and ERK2 showed no significant difference; whereas 
the expressions of phosphorylated ERKl and ERK2 increased significantly (Figure 
3.11). These results suggested that prolonged glucose deficiency induced the 
activation of ERK pathway in astrocytes. 
To examine whether the activation of ERK MAPKs is involved in the 
downregulation of GLT-1 in astrocytes upon glucose deficiency, we made used of the 
specific MAPK inhibitor. U0126 is an effective and specific inhibitor for MEK 
(Favata et. al_, 1998), which is the upstream kinase of ERK MAPK. Therefore, by 
inhibiting MEK, ERK MAPK cannot be activated by phosphorylation. We first 
determined the effect of U0126 on the cytotoxicity in astrocytes by MTT assay. 
Commonly used concentrations of U0126 range from 1 |aM to 100 \iM, and we used 0 
|j_M, 0.1 |.iM, 1 i^M and 10 fiM as the tested concentrations for the MTT assay. Results 
indicated that up to 10 |aM of U0126 used, no significant reduction of cell viability 
was observed (Figure 3.12). In addition, 10 fiM of U0126 was found to be effective in 
our astrocytic model (Data not shown; please refer to Appendix). 
10 jiM U0126 was used as the tested concentration for the following 
experiments in elucidating the effects of U0126 on the gene expression of GLT-1. 
From Figure 3.13, when 10 |aM of U0126 was added to astrocytes exposed to glucose 
deficiency, the downregulation of GLT-1 gene expression was abolished. As DMSO 
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was used as the solvent for U0126, we also tested for effects of DMSO on GLT-1 gene 
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Figure 3.11 Effects of glucose deficiency on the expressions of total and 
phosphorylated ERKl/2 in primary astrocytes. After the astrocyte culture were 
synchronized with 0.1% FBS for 48 hours, the cells were treated with media 
containing different glucose concentrations (1-3 mM). Total protein was extracted 5 
days after treatment as described in Section 2.2. Western blotting experiments were 
performed to determine the protein expressions of total ERKl/2 (A) and 
phosphorylated ERKl/2 (B). Cells incubated in the presence of 3 mM glucose was 
taken to unity and served as control. Results shown represent the 土 S.E. of three 
independent experiments. "*" signifies significant difference (p<0.05) by ANOVA on 
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Figure 3.12 Effect of different concentrations of U0126 on the cell viability of 
primary astrocytes. Primary astrocytes (5 x 10^ cells/ml) were seeded in a 96-well 
plates for 24 hours. Following the 48-hour synchronization, cells were treated with 
different glucose concentrations (1-3 mM) for 24 hours. After the incubation, MTT 
assay was performed according to the procedures described in Section 2.2. Results 
shown represent the 土 S.E. of three independent experiments. Statistics were done 
using ANOVA on Ranks (Dunnett's post-test) with the comparison between the 
control (3 inM). 
I 
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Figure 3.13 Gene expressions of GLT-1 upon glucose deficiency in primary 
astrocytes. After the astrocyte culture were synchronized with 0.1% FBS for 48 
hours, the cells were treated with different glucose concentrations (1-3 mM). 10 |_iM 
of U0126 or absolute DMSO were added 24 hours before cells were extracted. Total 
RNA was extracted 5 days after treatment as described in Section 2.2. RT-PCR 
experiments were performed to determine the gene expression of GLT-1. Results 
shown represent the 土 S.E. of three independent experiments. Statistical analysis was 




CHAPTER 4 DISCUSSION AND CONCLUSION 
4.1 Role of Astrocytes in Preventing Glutamate Excitotoxicity under Glucose 
Deficiency 
Astrocytes, the most abundant cell type in the CNS, are the major sites for the 
homeostasis of extracellular glutamate level by the action of glutamate transporters 
(Anderson and Swanson, 2000). However, when there are defects in the glutamate 
uptake mechanism, an accumulation of glutamate at the synapse and consequently an 
overstimulation of glutamate receptors would occur, leading to seizure (Meldrum et. 
al., 1999; Watanabe et. al., 1999). Extensive studies focusing on ischemia had 
demonstrated that acute oxygen-glucose deprivation (OGD) would lead to a drastic 
increase in extracellular glutamate (Choi and Rothman, 1990). Based on the findings, 
we hypothesized that prolonged glucose deficiency would impair the glutamate 
uptake in astrocytes, creating a pro-epileptic condition. 
4.1.1 Neonatal Astrocytes as the Cell Model for Chronic Glucose Deficiency 
In Glut lDS patients, epileptic symptoms usually starts during their early infancy 
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(De Vivo et. ciL, 2002). Glutamate excitotoxicity, which may be one cause of epilepsy, 
is partly related to the inability to take up excessive glutamate by astrocytes. In order 
to examine the role of astrocytes in the development of epilepsy under glucose 
deficiency, we established an in vitro model using neonatal rat astrocytes. With the 
higher growth rates of neonatal astrocytes over oligodendrocytes and microglia, a 
relatively high purity astrocyte culture can be obtained (McCarthy and de Vellis, 
1980). • 
Recent researches have been focused on studying the acute effects of glucose 
deprivation on proliferation, toxicity and apoptosis in brain cells (Martinez-Sanchez et. 
ciL, 2004; Kansara and Berridge, 2004; Ishii et. ciL, 2004). The conditions in these 
studies may not simulate those in diseases related to prolonged glucose deficiency 
such as Glutl DS. Thus, we established an in vitro model by exposing astrocytes with 
different glucose concentrations (1，2 and 3 mM) for 5 days. Under normal 
physiological conditions, the glucose concentration in the CSF is around 2.7 mM, so 
the 3 mM glucose-treated group in this system represented the normal state. In 
diseases such as Glut IDS，the cerebral glucose level would drop to around 2 mM, so 
> 
the 1 and 2 mM glucose-treated groups in the experiments represented the glucose 
deficient conditions. 
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4.1.2 Effects of Glucose Deficiency on the Expressions of Glutamate Transporters 
and Glutamate Uptake 
In response to the 5-day exposure of glucose deficiency, the gene and protein 
expressions of GLT-1 decreased, whereas those of GLAST did not change 
significantly. This indicates the specificity of glucose deficiency on glutamate 
transporter expression. Activation of the ERK pathway has been shown to inhibit 
glutamate uptake in astrocytes (Abe and Misawa, 2003). We therefore determined the 
effects of glucose deficiency on the ERK MAPKs. From our results, it was suggested 
that when the glucose concentration was reduced to 1 mM, both the phosphorylated 
form of ERKl and ERK2 increased. In addition, 10 |j.M of the MEK (the upstream 
kinase of ERKl/2) inhibitor, U0126, successfully blocked the glucose 
deficiency-induced reduction of GLT-1 gene expression, supporting the involvement 
of ERKl /2 in regulating glutamate homeostasis under glucose deficiency. 
The alteration of ERK 1/2 activities may be due to a change in the intracellular 
signaling mechanism upon the sensing of reduced glucose by astrocytes. Studies in 
> 
yeast suggested that yeast senses glucose by two modified glucose transporters 
serving as glucose receptors (Ozcan et. al., 1998). Similar mechanisms may be 
present in mammalian cells in which ERXl/2 may be one of the downstream 
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signaling pathway. 
It is important to note that the possible involvement of other signaling 
mechanisms in regulating glutamate transport under glucose deficiency cannot be 
excluded. For instance, astrocytic GLT-1 expressions were found dependent on 
phophatidylinositol 3-kinase and N F K B (Zelenaia et. al., 2000). Besides, extensive 
studies also showed the relationship between glutamate transport and the protein 
kinase C signaling pathway (Zhou and Sutherland, 2004; Kalandadze et. al., 2002; 
Ahlemeyer et. al, 2002; Othman et. al., 2002; Susarla et. al., 2004). 
With the reduction in GLT-1 expressions, it was speculated that the glutamate 
uptake from the extracellular space would decrease accordingly. Studies concerning 
the acute effects of glucose deficiency reported the reduction of GLT-1 expressions 
and glutamate uptake in astrocytes (Jabaudon et. al., 2000; Yeh et. al., 2005). 
However, our results on glutamate uptake and the glutamate clearance assays 
indicated that prolonged glucose deficiency did not cause any observable difference in 
glutamate uptake in astrocytes. Thus, we explored the possibility that the effect of 
prolonged glucose deficiency on the expression of GLT-1 was compensated by other 
mechanisms triggered by glucose deficiency. 
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4.1.3 Cytokines: Mediators for Energy Production in Astrocytes 
GLT-1 and GLAST are Na^-dependent glutamate transporters. This transport 
system is coupled with the action of Na+/K+ ATPase, suggesting that the uptake of 
glutamate from the extracellular space requires energy which comes from the 
metabolism of glucose. The possibility that under prolonged glucose deficiency, the 
reduction of GLT-1 expression was compensated by increased energy supply was 
explored. 
In order to boost energy production under glucose deficiency, the glucose 
transport systems in astrocytes needs to be upregulated. As glucose is mainly taken up 
through the Glutl transporters in astrocytes (Wong et. al., 2005b), we first examined 
the expression of Glutl and glucose uptake under glucose deficiency. The results, it is 
demonstrated that as the glucose supply reduces, astrocytes compensated by 
increasing the expression of Glutl and glucose uptake. 
Glucose uptake via Glutl transporters in astrocytes was found to be affected by 
a variety of substances, including ammonia, anticonvulsant drugs and inflammatory 
cytokines (Belanger et. al., 2006; Wong et. al., 2005a; Wong et. al., 2005b; Wong, 
2005; Saito et. al, 1996). In the present study, we focused on investigating the effects 
of glucose deficiency in triggering inflammatory cytokine expressions, leading to an 
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increase in glucose uptake in astrocytes. Our results showed that astrocytes exhibited 
differential expression profiles for different cytokines when the glucose supply was 
reduced, indicating that the cytokines being altered (i.e. I L - l a and IL-6) may have 
specific functions other than inducing inflammation under prolonged glucose 
deficiency. 
With the various neuroprotective roles of IL-6 (De Jongh et. al, 2003), we 
focused on investigating the relationship between cytokines and glucose uptake. Our 
results showed that for astrocytes treated with 2 mM or 3 mM glucose, the glucose 
uptake increased significantly upon the addition of 10 ng/ml of IL-6. For cells treated 
with 1 mM glucose which already had elevated IL-6 production level, glucose uptake 
was not further enhanced upon the addition of IL-6, indicating that such prolonged 
glucose deficiency condition may produce an effect similar to the action of IL-6 on 
glucose uptake in astrocytes. Such observation was consistent with the previous 
findings that externally added IL-6 could upregulate Glutl protein expression and 
glucose uptake in astrocytes incubating in high glucose-containing medium (Wong, 
2005). 
> 
Different signaling pathways were suggested to be related to glucose uptake in 
various cell types. For instance, PKC and MAPKs pathways were found to be 
responsible for the uptake of 2-deoxyglucose in mouse embryonic stem cells (Heo and 
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Han, 2006). In cardiac myoblasts, glucose transport induced by ischemia was 
mediated by PKC-delta and ERKl/2 pathways (Agnetti et. al, 2005). However, the 
present study has not investigated the signaling pathway underlying the IL-6-induced 
glucose uptake in astrocytes. Nevertheless, ERKl/2 activation was found to correlate 
with the expression of IL-6 in astrocytes (Lee et. al., 2000). 
The mRNA level of IL - l a was found to decrease significantly under prolonged 
glucose deficiency. For years, there were few studies focused on IL- la . This is 
because after the cleavage of the pro-IL-la , the mature proteins remain inside the cell 
except upon cell death (Allan et. al., 2005). However, due to the similarities in the 
sequence, I L - l a and IL-ip are believed to exert similar biological effects. It has been 
shown that IL- la , when introduced with other cytokines, could enhance the 
neurotoxic effects (Chao et. al., 1995). Studies also revealed the roles of IL - l a in the 
promotion of astrogliosis (Keung, 2003) and the expressions of mediators which are 
potentially neurotoxic (John et. al., 2005). Extensive studies also uncovered the 
importance of I L - l a in inflammation and the relationship with various 
neurodengerative diseases (Kornman, 2006). Taken together, the reduction of IL- l a 
expression, the unchanged IL-ip expression and the increase in IL-6 secretion under 
glucose deficiency appeared to be beneficial to the astrocytes and perhaps the CNS. 
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4.1.4 Summary of the Roles of Astrocytes under Prolonged Glucose Deficiency 
Based on previous findings on epilepsy, we hypothesized that prolonged glucose 
deficiency impairs the glutamate uptake mechanism in astrocytes, leading to the 
pro-epileptic condition of extracellular glutamate accumulation. However, our results 
suggested that glucose deficiency, though downregulated the expressions of GLT-1 via 
the ERK pathway in astrocytes, the glutamate uptake function was not affected. This 
is likely due to the compensation of astrocytic release of lL-6, a cytokine found to 
stimulate the glucose uptake system and in turn improve energy availability in 
astrocytes (Figure 4.1). 
The activation of ERK pathway upon prolonged glucose deficiency might 
possess other functions. For instance, it was found that ERK MAPKs mediated 
protections against neuronal injury induced by amyloid-P protein (Yamamuro et. al, 
2003). ERK 1/2 was also found to mediate neuroprotection by activating glial 
metabotropic glutamate receptors (D'Onofrio et. al, 2001). In addition, previous 
findings suggested that glucose deficiency induced the neurotrophic properties in glial 
cells which may be related to the ERK pathway (Lai, 2006). Thus, we suspected that 
the reduction of GLT-1 expression was a side effect of ERK activation, and astrocytes 
compensated it by increasing the intracellular energy availability. 
88 
Figure 4.1 shows the schematic model of astrocytic responses to glucose 
deficiency with a focus on glutamate uptake under prolonged glucose deficiency 
based on the results obtained in this thesis project. 
Glucose 
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J l ERICl/2 Glutamate 
Activation Concentration 
c r 暴 E 二 — — 
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Figure 4.1 A schematic model showing the role of astrocytes in the glutamate 
homeostasis under prolonged glucose deficiency. Astrocytes respond to glucose 
deficiency by ERKl/2-dependent suppression of GLT-1 glutamate transporter 
expression. Such response did not change the glutamate uptake function indicating the 
presence of compensatory mechanisms. One possible compensatory mechanism in 
response to glucose deficiency is to boost energy availability by increase glucose 
uptake through the induction of IL-6 secreted by astrocytes. 
4.2 Establishment of an in vitro GlutlDS model 
> 
Glutl DS is characterized by a reduced functional Glutl expressions and a 
prolonged glucose deficiency in the brain (De vivo et. al., 2001). From our study, 
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astrocytes are suspected to possess neurotrophic roles under glucose deficiency. Thus, 
we are also interested in investigating the effects of Glutl deficiency on astrocytes. 
In order to establish a cell model for Glutl deficiency, RNA interference was 
used. Traditionally, different approaches had been discovered for gene silencing 
including antisense techniques and introduction of dominant-negative mutants. 
However, complementation and specificity to the target are usually the main problems 
(Porter, 1998). In comparison, gene silencing by double-stranded RNA (dsRNA) is 
believed to be a powerful gene silencing agent. In addition, dsRNA of 21 bp was 
found to be effective in mammalian cells (Elbashir et. al., 2001). 
We have performed initial work on the establishment of the Glutl-deficiency 
model by transfecting the Glutl siRNA-bearing vector into C6 glioma cells, and the 
preliminary results are included in the Appendix. 
4.3 Future Directions of the Project 
The present study showed the effects of prolonged glucose deficiency on 
astrocytic responses. However, normal functioning of the brain requires the 
interactions between neurons and supporting cells such as astrocytes. In order to 
investigate the relationship between the altered astrocytic properties and neuronal 
90 
survival, an astrocytic-neuronal co-culture may be used in the future. 
The compensation to reduced GLT-1 expression upon glucose deficiency was 
suspected to be due to an increase in energy availability in the cell. ATP, the universal 
energy source, is derived from glucose metabolism in the cell. In the present study, we 
found that IL-6 secreted from astrocytes under glucose deficiency was related to an 
increase in glucose availability in the cell. In order to ensure whether the increase in 
glucose in the cell corresponds to an increase in ATP formation, the ATP content in the 
cells upon prolonged glucose deficiency can be measured. Besides, upon abolishing 
the effects of IL-6 by using IL-6 receptor antagonists, one can investigate its 
involvement in glucose uptake and glutamate uptake in astrocytes. In addition, the 
involvement of the ERK 1/2 pathway in astrocyte growth and cytokine expressions 
under prolonged glucose deficiency should be further studied. 
Another possibility of the unchanged glutamate uptake upon the reduction of 
GLT-1 expression is that the activities of the glutamate transporters, both GLT-1 and 
GLAST, increase. To test this hypothesis, glutamate uptake assay may be performed 
with the addition of specific blockers to the two major glutamate transporters, e.g. 
> 
dihydrokainate for GLT-1 (Zschocke et. al, 2005) and L-threo-P-hydroxyaspartate for 
GLAST (Kojima et. al., 1999). 
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4.4 Conclusion 
From the results of the present project in studying the effects of prolonged 
glucose deficiency on the glutamate uptake mechanism in astrocytes, the following 
conclusions were drawn: 
1. The involvement of IL-6 in increasing energy availability in astrocytes may 
compensate for the ERKl/2-mediated downregulation of GLT-1 under prolonged 
glucose deficiency. 
2. Decreased glutamate uptake by astrocytes may not be the cause for the epileptic 
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U0126 inhibits phosphorylated ERKl/2 expression. After the astrocyte culture was 
synchronized with 0.1% FBS for 48 hours, the cells were treated with media 
containing different glucose concentrations (1-3 mM). 24 hours before extraction, 
different concentrations (0.1-10 |j,M) of U0126 were added. Total protein was 
extracted as described in Section 2.2. Western blotting experiments were performed to 
determine the expression of phosphorylated ERKl/2. 
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APPENDIX 
2. Information on the Experiments of RNA Interference 
Section 1: Materials and Methods 
Rat C6 Glioma Cells 
The cell line was purchased from the American Type Culture Collection 
(A.T.C.C., Manassas, V.A., U.S.A.). The cells were originally cloned from the rat glial 
tumor induced by N-nitrosomethylurea after alternate culture and animal passages 
(Benda et. al., 1968). Cell passages from 15 to 30 were used for the experiments in 
this project. 
Preparation of siRNA-bearing Vector 
The p S i l e n c e r ^ ^ hygro siRNA Expression Vector Kit (Ambion, Inc., Austin, 
T.X., U.S.A.) includes 4 components: linearized pSilencer^^ hygro siRNA Expression 
Vector, circular negative control p S i l e n c e r ^ ^ hygro vector (0.5 GFP-specific 
hairpin siRNA insert (80 ng/|^l) and Ix DNA Annealing Solution. The kit was stored < 
at -20"C until use. Two complementary hairpin siRNA templates targeting the Glutl 
mRNA were designed according to the criteria suggested in the pSilencer^^ hygro Kit 
manual (Table 1). Diethyl pyrocarbonate (DEPC) was purchased from GE. Healthcare, 
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Buckinghamshire, U.K. T4 DNA ligase (5 U/^il) and lOx T4 DNA ligation buffer 
were purchased from Fermentas, Hanover, M.D., U.S.A. 
Sequences (5，to 3，） 
5, -G ATCCCGCTCC ATGCTG ATG ATG A ACCTGTTC A AG Sense AGACAGGTTCATCATCAGCATGGAGTTTTTTGGAAA-3' 
. 5 ’-AGCTTTTCCAAAAAACTCCATGCTGATGATGAACC An tisense TGTCTCTTGAACAGGTTCATCATCAGCATGGAGCGG-3' 
Table 1 The complementary hairpin siRNA templates targeting the Glutl 
mRNA from 5，to 3，. 
Transformation into Escherichia coli (E. coli) Cells 
Competent E . c o l i strain DH5a stock for transformation was kindly provided by 
Prof. K. B. Wong (Department of Biochemistry, The Chinese University of Hong 
Kong, H.K.S.A.R., China). Luria broth (LB) and LB agar were purchased from GE. 
Healthcare, Buckinghamshire, U.K. Ampicillin (50 |ig/ml) was prepared by dissolving 
ampicillin sodium salt (GE. Healthcare, Buckinghamshire, U.K.) in autoclaved water. 
Wizard® P l u s SV Minipreps DNA Purification System was purchased from Promega, 
Madison, W.I., U.S.A. A pair of primers was designed for confirming the correct 
insert' of the clone by PCR and sequencing (Table 2). 
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Primer Sequence (5，to 3，） Size (bp) 
5 ’ primer GTAATACGACTCACTATAGGG 534 3 ’ primer AGGCGATTAAGTTGGGTA 
Table 2 Primer sequences for checking PCR and sequencing of the 
selected colonies. 
Reagents for siRNA Transfection 
Lipofectamine'^ 2000 Transfection Reagent was purchased from Invitrogen, 
Carlsbad, C.A., U.S.A. 
Maintenance of C6 Glioma Cells 
C6 glioma cells were cultured with complete high glucose D-MEM containing 
10% FBS and 1% PS in an 37"C incubator with 5%/95% COs/air. The cells were 
SLibcultured upon reaching 80% confluence according to the procedures described in 
Lung et. al. (2005). Briefly, the medium was firstly aspired, and the cells were washed 
with Ix PBS and were treated with 0.05% trypsin-EDTA at 37°C for 5 minutes. Then 
the cell suspension was centrifuged at 1,000 rpm for 5 minutes at room temperature. 
The cell pellet was dispersed and resuspended with complete high glucose D-MEM. 
One-tenth of the resuspended cell was cultured in a new 75 cm^ culture flask > 
containing 15 ml of complete high glucose D-MEM. 
Ill 
Preparation of siRNA-bearing Vector 
The sense and the antisense oligonucleotides, 1 |.ig/|-il, were mixed with Ix DNA 
annealing solution for the annealing process. The mixture was firstly incubated at 
90"C for 3 minutes, then cooled to Y f C for 1 hour. The annealed inserts were 
subjected to ligation into the ^ S i l e n c e r vector by incubating the reaction mixture 
(Table 3) at 16�C overnight. 
Diluted annealed insert (8 ng/|j.l) 1 
Nuclease-free water 6 
1 Ox T4 DNA ligase buffer 1 i^l 
p S i l e n c e r vector 1 
丁4 DNA ligase (5 U/|al) 
Total volume: 10 \i\ 
Table 3 The reaction mixture for the ligation reaction. 
Transformation into E. coli Cells 
The insert-bearing vector was put into E . c o l i cells through transformation. 
Firstly, the plasmid was mixed with the competent cells allowed to stand for 15 
minutes on ice, then heat shock was performed by incubating the mixture at 42"C for 
2 minutes. After cooling on ice for 2 minutes, cells were recovered in y f C LB broth 
with shaking for 30 minutes. The cells were collected by centrifugation at 8,000 rpm 
for 1 minute and resuspended in LB broth. The resuspended cells were evenly spread 
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over a LB agar plate containing 50 |j.g/ml of ampicillin and incubated at 3TC 
overnight. 
A total of 3 colonies were selected from each LB agar plate, and PCR reactions 
were performed to check for confirming the insert. The PCR conditions were 94®C for 
5 minutes, and 20 cycles of 94°C for 30 seconds, 55°C for 1 minute and 72"C for 1 
minute, followed by 72"C for 5 minutes. Plasmic DNA from the positive clones 
confirmed were allowed to grow overnight in the LB broth, then extracted by a 
miniprep DNA purification kit. The plasmids were subjected for sequencing 
(Macrogen Inc., Seoul, Korea). 
siRNA Transfection 
The following protocol for transfection of siRNA into C6 glioma cells was 
adopted from the manual of Lipofectamine^'^ 2000 Transfection Reagent. Briefly, 24 
hours after seeding the cells in 24-well plates, the complete medium was changed to a 
medium containing no FBS and PS incubated for 40 minutes at 3TC. Then, the 
pre-mix transfection reagent and the siRNA-bearing plasmid were added to the cells 
(v/v of plasmid to Lipofectamine"^ 2000 was 1 :5). After incubation for 6 hours at 
37"C, the medium was changed to a complete medium. 
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Section 2: Results 
Establishment of an In Vitro Model for GlutlDS 
GlutlDS is characterized with Glutl haploinsufficiency and prolonged reduction 
of glucose level in the brain. With the initial investigation of the effects of glucose 
deficiency in astrocytes, we tried to establish an in v i t r o model for studying the effects 
of Glutl deficiency. C6 glioma cells were widely used as a model for astrocytes in 
which C6 cells have short population doubling time (Lai, 2005) and high transfection 
efficiency, so C6 cells were adopted in the present study. 
Effects of Glucose Deficiency in C6 Glioma Cells 
In order to compare the effects in primary astrocytes and C6 glioma cells, we 
first examined the effects of glucose deficiency in C6 cells, in terms of the 
expressions of cytokines and glutamate transporters. The results revealed that under 
glucose insufficiency, the gene expressions of IL- la , IL-6 and GLT-1 showed similar 
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Figure 1 Effects of glucose deficiency on the gene expressions of IL- la , IL-6 and 
GLT-1 in C6 glioma cells. After C6 cells (19,500 cells/ml) were seeded in 100 mm 
dishes for 24 hours, the culture was synchronized with 0.1% FBS for 48 hours. Then 
the cells were treated with different glucose concentrations (1-3 mM). Total RNA was 
extracted 5 days after treatment as described in Section 2.2. RT-PCR experiments 
were performed to determine the gene expressions. Results shown represent the 土 S.E. 
of three independent experiments. "*" signifies significant difference (p<0.05) by 
ANOVA on Ranks (Dunnett's post-test) when compared with the control (3 mM). 
> 
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Glutl Gene Knockdown by RNA Interference 
Starting from 1998, specific genes can be made silence by a technique called 
RNA interference (Fire et. al, 1998). Upon the association of the RNAi-induced 
silencing complex and the target mRNA, mRNA translational repression or mRNA 
cleavage would occur (McManus and Sharp, 2002). 
The siRNA specific for Glutl was designed. After ligation of the two siRNA 
templates into the vector and transformed into the E . c o l i . cells, colonies grown on the 
ampicillin agar plate were collected to confirm whether the colonies contained the 
correct vector. PCR reactions were performed, using the designed primers, to confirm 
the size of the siRNA-bearing vector. From the gel photo, a sharp band with a size of 
around 500 kb was observed (Figure 2A). In addition, after DNA isolation, 1 \ig of 
plasmid was taken out for DNA sequencing. From the result, we confirmed the 
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Figure 2 Confirmation of the siRNA-bearing plasmid. A) Colonies grown on the 
ampicillin agar plate were collected and used as templates for the PCR reaction. The 
arrow points to the band corresponding to the siRNA-bearing plasmid. B) After DNA 
extraction and purification, 1 |ig of DNA was sujected for sequencing. The result was 
shoyn in peaks and the corresponding nucleotides were represented in letters above 
the peaks. 
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Transient Transfection of C6 Glioma Cells 
C6 glioma cells were found successfully transfected using various transfection 
reagents including Lipofectamine"^ 2000 transfection reagent and Lipofectamine�M 
transfection reagent (Esteve et. al, 2002; Gudi et. al, 2002). To confirm the 
SLiccessfulness of transient transfection in C6 cells using our system, we transfected 
the GFP-bearing vector into C6 cells with the Lipofectamine^"^ 2000 transfection 
reagent. One day after transfection, the cells were observed under a fluorescent 
microscope. From the microscopic picture, we observed that upon the excitation, GFP 






Figure 3 Transfection efficiency shown by the fluroscent signal of the 
GFP-transfected cells. GFP-bearing vector was transfected into C6 cells according to 
the procedures described in Section 2.2. One day after transfection, the cells were 
seen under a fluorescent microscope with a lOx magnification. The upper panel 
showed the cells which were exposed to ordinary light (A). The lower panel showed 
the cells which were excited by blue light (B). 
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Glutl siRNA Transfection in C6 Glioma Cells 
After confirming the transfection efficiency in C6 cells, we transfected our 
siRNA-bearing vector in the C6 cells. In order to compare the results with the glucose 
deficiency experiments in astrocytes, we first synchronized the cells with 0.1% FBS 
for 48 hours. After 6 hours of transfection, the cells were incubated in 3 mM 
glucose-containing medium for 5 days. The gene expression of Glutl was determined 
to examine the effects of siRNA transfection. From the RT-PCR result, we observed a 
significant reduction of Glutl mRNA level (p<0.05) when compared with the 
untransfected control, suggesting the transfection of siRNA in C6 cells were 
successful. For the cells treated only with Lipofectamine^^ 2000, though it showed a 
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Figure 4 Knockdown of Glutl gene expression in siRNA-transfected C6 cells. C6 
cells (19,500 cells/ml) were plated in 24-well plates for 24 hours, followed by a 
48-hour synchronization with 0.1% FBS. The transfection of siRNA-bearing vector 
was according to the procedure described in Section 2.2. 5 days after transfection. 
total RNA was extracted for RT-PCR experiments. Results shown represent the 土 S.E. 
of three independent experiments. ‘‘*，，signifes significant difference (p<0.05) by 
ANOVA on Ranks (Dunnett's post-test) when compared with the control (3 mM). 
“Lipo’’ represents the cells treated with Lipofectamine™ 2000 only. 
> 
121 
Effects of the Glutl Knockdown in C6 Glioma Cells 
In determining the effects of Glutl insufficiency and comparing them with the 
effects in glucose deficiency in C6 cells, we examined the expressions of a number of 
genes including IL- la , IL-6 and GLT-1 after the transfection of siRNA. From the 
results, we observed that IL - l a and GLT-1 showed significant increases in the 
expressions (p<0.05), while for IL-6 gene, it showed a significant decrease (p<0.05) 
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Figure 5 Effects of Glutl siRNA transfection on the gene expressions of IL- la , 
IL-6 and GLT-1 in C6 glioma cells. C6 cells (19,500 cells/ml) were plated in 24-well 
plates for 24 hours, followed by a 48-hour synchronization with 0.1% FBS. The 
transfection of siRNA-bearing vector was according to the procedure described in 
Section 2.2. 5 days after transfection, total RNA was extracted for RT-PCR 
experiments. Results shown represent the 士 S.E. of three independent experiments. 
‘‘*,’ signifies significant difference (p<0.05) by ANOVA on Ranks (Dunnett's 
post-test) when compared with the control (3 mM). "Lipo" represents the cells treated 
with Lipofectamine '^ 2000 only. 
» 
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